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vitamin K antagonistAtrial fibrillation (AF) is the most common sustained arrhythmia. Both the incidence and prev-
alence of AF are increasing, and the burden of AF is becoming huge. Many innovative advances
have emerged in the past decade for the diagnosis and management of AF, including a new
scoring system for the prediction of stroke and bleeding events, the introduction of non-
vitamin K antagonist oral anticoagulants and their special benefits in Asians, new rhythm- and
rate-control concepts, optimal endpoints of rate control, upstream therapy, life-style modifica-
tion to prevent AF recurrence, and new ablation techniques. The Taiwan Heart Rhythm Society
and the Taiwan Society of Cardiology aimed to update the information and have appointed a
jointed writing committee for new AF guidelines. The writing committee members comprehen-
sively reviewed and summarized the literature, and completed the 2016 Guidelines of the
Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the Management of Atrial
Fibrillation. This guideline presents the details of the updated recommendations, along with
their background and rationale, focusing on data unique for Asians. The guidelines are not
mandatory, and members of the writing committee fully realize that treatment of AF should
be individualized. The physician’s decision remains most important in AF management.
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Many innovative advances have emerged in the past decade
for the diagnosis and management of atrial fibrillation (AF),
including epidemiological information, a new scoring sys-
tem for the prediction of stroke and bleeding events, the
introduction of non-vitamin K antagonist oral anticoagu-
lants (NOACs) and the their special benefits in Asians, new
rhythm- and rate-control concepts, optimal endpoints of
rate control, upstream therapy, lifestyle modification to
prevent AF recurrence, and new ablation techniques. The
Taiwan Heart Rhythm Society and the Taiwan Society of
Cardiology aimed to update the information and have
appointed a jointed writing committee for new AF guide-
lines. Although writing committee members comprehen-
sively reviewed and summarized the literature, the search
of publications was not systemic and new data are
emerging rapidly. Nevertheless, recommendations or sug-
gestions in the guidelines were developed by experienced
experts in Taiwan and were agreed on by consensus or
majority decision. We have not graded the quality of evi-
dence objectively or systemically.
The 2016 Guidelines of the Taiwan Heart Rhythm Society
(THRS) and the Taiwan Society of Cardiology (TSOC) for the
management of AF provide the most updated information
about AF, focusing on data unique for Asians. The guidelines
are not mandatory, and members of the writing committee
fully realize that treatment of AF should be individualized.
The physician’s decision remains most important in AF
management.
1. Epidemiology
1.1. Atrial fibrillation in the world
AF is the most common cardiac arrhythmia. The lifetime risk
of developing AF for adults is about 20e25%, similar in white
people and in Chinese.1e3 According to recently published
data from the Global Burden of Diseases 2010 study,4 the
estimated global prevalence of AF in 2010 was 33.5 million,including 20.9 million men, and 12.6 million women. It is
possible that these numbers were underestimated, since
many asymptomatic AF patients could be undetected.5 Be-
tween 1990 and 2010, there were significant increases in the
estimated age-adjusted prevalence and incidence of AF.4
The annual new cases of AF globally in 2010 were esti-
mated at close to 5 million.4 Burden associated with AF,
measured as disability-adjusted life-years, increased by
18.8% in men and 18.9% in women from 1990 to 2010.4 Mor-
tality associated with AF was higher in women and increased
by 2-fold and 1.9-fold in men and women, respectively.4
The exact reasons for these trends are unknown, but
they may be explained by ageing trends and an increase in
the prevalence of obesity.4,6 Other contributing factors
include increase in the prevalence of diabetes,7 heart
failure,8 obstructive sleep apnea syndrome,9 and improved
survival following myocardial infarction (MI).
1.2. Atrial fibrillation in Asia
According to several Asian cohort studies and registries, the
prevalence rate of AF in most of the Asian countries is
around 1% in the adult population (Figure 1), lower than
that in white people (about 2%).10,11 Two recent reports
from the USA also confirmed a lower incidence rate of AF in
Asians compared with the white population.12,13 About half
of the total population in the world are living in Asia, and
elderly population is growing fast in Asia. The burden of AF
in Asia will become huge.14 In 2050, there will be 72 million
AF patients in Asia,14 more than double the combined
numbers of patients from Europe and the USA.15,16
1.3. Atrial fibrillation in Taiwan
According to a community-based cohort study in Taiwan,
the incidence rates of AF were 1.68 per 1000 personeyears
for men and 0.76 per 100 personeyears for women; the
overall prevalence of AF in Taiwanese is 1.4% in men and
0.7% in women.17 The prevalence and incidence of AF
increased substantially with age17 and are consistent with
1.6
0.7
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Figure 1 Prevalence rate of atrial fibrillation in Asian
countries.
2016 AF Guidelines of THRS/TSOC 897cross-sectional survey data in the USA, where the AF
prevalence ranged from 0.1% among adults younger than
55 years to 9% among octogenarians.10 In hospitalized pa-
tients, a nationwide hospital-based data analysis showed
that the mean annual frequency of diagnosed AF was 127
per 100,000 persons for Taiwanese and was higher in men
than in women (137 per 100,000 vs. 116 per 100,000).18 The
analysis also demonstrated that although there was an
upward linear trend in the annual frequency of patients
with AF, the trends of in-hospital mortality rate
decreased,18 which was in accord with a recent nationwide
inpatient survey in the USA.19
2. Mechanism and pathophysiology
2.1. Atrial structural remodeling
Any kind of structural heart disease may trigger a slow but
progressive process of structural change or remodeling in
both the ventricles and the atria. In the atria, enhanced
connective tissue deposition and fibrosis are the hallmarks
of this process. The cellular mechanisms may involve acti-
vation of the renineangiotensin system,20 triggering of in-
flammatory response, and an increase in oxidative stress.21
Structural remodeling consists of electrical dissociation
between muscle bundles, local conduction heterogeneities,
and conduction slowing. These changes may facilitate the
initiation of multiple small re-entrant circuits, and
perpetuate AF. Several clinical situations are commonly
associated with atrial structural abnormalities, such as
congestive heart failure, ventricular hypertrophy and dila-
tion, myocardial ischemia and infiltrative diseases.
2.2. Electrophysiological mechanisms
The initiation and perpetuation of AF requires both triggers
for its onset and a substrate for its maintenance. These
mechanisms are not mutually exclusive and are likely to
coexist at various stages of AF. Focal rapid firing in a locus
of the atrium (focal mechanism) may potentially contribute
to the initiation and perpetuation of AF.22 Cellularmechanisms of focal activity may involve increased auto-
maticity (autonomic nervous system activation), triggered
activity (abnormal calcium handling and autonomic nervous
system activation), and microreentry. Due to shorter action
potential duration and abrupt changes in the orientation of
myocyte fiber, the pulmonary veins (PVs) and their adja-
cent areas have a stronger potential to initiate and
perpetuate atrial tachyarrhythmias, particularly in parox-
ysmal AF. In persistent AF, potential sources of focal
mechanism may reside in sites throughout the entire atria.
Another mechanism for the perpetuation and mainte-
nance of AF is the multiple wavelet theory. According to the
multiple wavelet theory, AF is perpetuated by continuous
conduction of several independent wavelets propagating
through the entire atria. Fibrillation wavelets continuously
undergo wavefrontewaveback interactions, resulting in
wave-break and the generation of new wavelets, while
block, collision, and fusion of wavelets tend to reduce their
number. As long as the number of wavelets does not decline
below a critical level, the multiple wavelets will sustain the
arrhythmia. The number of wavelets is in reverse relation-
ship to action potential duration. Action potential duration
of atrial myocytes tends to shorten when the duration of AF
prolongs, an adaptive process called electrical remodeling.
Therefore, when the duration of AF prolongs, THAT fibrilla-
tion wavelet becomes more and more stable, because the
number of wavelet increases (AF begets AF). It is widely
accepted that this multiple wavelet theory plays a more
important role in the pathophysiology of persistent or per-
manent AF than in paroxysmal AF. By contrast, focal firing
may be more important in sustaining paroxysmal AF.
Another evolving electrophysiological mechanism of AF
is the combination of focal mechanism and multiple
wavelet theory, in which the conducting multiwavelets are
driven by single or several mother rotors or major reentry
circuits.23 The evidence came from onsite mathematical
signal analyses of multisite local electrograms throughout
the atria during AF ablation, which revealed driving rotors
perpetuating the rhythm of AF.24 Furthermore, ablation of
driving rotor(s) could successfully terminate AF.25 This
mechanism may contribute to the maintenance and
perpetuation of any type of AF. However, the effectiveness
of this ablation strategy has to be confirmed in more clinical
trials.
2.3. Genetic predisposition
AF has a familial component, especially in patients with
early-onset AF. Many inherited cardiac syndromes or
channelopathies associated with AF have been identified
recently. Both short and long QT syndromes and Brugada
syndrome are associated with supraventricular arrhyth-
mias, including AF. AF also frequently occurs in a variety of
inherited conditions, including hypertrophic cardiomyopa-
thy and dilated cardiomyopathy. Some familial forms of AF
are associated with mutations in the genes coding for atrial
natriuretic peptide, loss-of-function mutations in the car-
diac sodium channel gene SCN5A, or gain of function in
cardiac potassium channels. Furthermore, several genetic
loci close to the KCNN3, PRRX1, PITX2, WNT8A, CAV1,
C9orf3, SYNE2, HCN4, and ZFHX3 genes, identified by
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898 C.-E. Chiang et al.genome-wide association studies, have been shown to be
closely associated with the risk of nonfamilial or common
AF.26,27 The pathophysiological role of these genetic de-
fects in the initiation and perpetuation of AF is currently
unknown. The associations of PITX2 and KCNN3 genes with
AF have been replicated in our Taiwanese population.28,29
3. Comorbidities of atrial fibrillation
Patients with AF generally have multiple cardiovascular (CV)
comorbidities.30 It has become difficult to identify patients
with lone AF, which is a diagnosis of exclusion whereby no
comorbid CV diseases could be found.31 In the RealiseAF
survey, just 5% in the total population and 3% in the
Taiwanese population had lone AF.30,32 Table 1 shows
several important stroke-related CV comorbidities or risk
factors in recent cohort studies or registries,30,33e43 In
general, the prevalence rate of these risk factors were
comparable among Asians and non-Asians. About 20e30% of
patients had congestive heart failure, and 60-70% had hy-
pertension. The mean age was around 70 years. Type 2
diabetes was identified in about 20e30% of patients. A
higher prevalence rate of a history of previous stroke or
transient ischemic attack (TIA) was found in Asians. Coro-
nary heart disease (CHD) seemedmore common in non-Asian
cohorts. About 40% of Asians and non-Asians were female.
As AF progressed from paroxysmal to persistent and per-
manent forms, the prevalence of comorbidities, such as
heart failure, CHD, cerebrovascular disease, and valvular
disease, increased, and the prevalence of lone AF
decreased.38,44 Permanent AF is a high-risk subset of AF,44
and> 80%of these patients had at least one comorbidity.44,45Recommendation
 In patients with AF, detailed history of comorbid-
ities, including hypertension, heart failure, CHD,
diabetes mellitus, and previous stroke, should be
obtained.4. Outcomes in patients with atrial fibrillation
Patients with lone AF have a benign prognosis. In a 30-year
follow-up study from the USA, patients with lone AF and a
mean age of 44 years had a similar survival, risk of heart
failure, and risk of stroke or TIA, compared to matched
control up to 25 years of follow-up.46 The largest lone AF
study demonstrated that these patients do have a favorable
prognosis as long as they have truly lone arrhythmia.47
However, with ageing and/or the occurrence of CV
comorbidities in such patients, the risk of development of
AF-related complications (e.g., thromboembolic events or
heart failure) increases.47
Most AF patients have increased risk of future CV events.
In general, white AF patients had two-fold risk of death,
three-fold risk of hospitalization, and five-fold risk of
stroke, compared with patients without AF.48e51 Similarly,
Asian AF patients had two-fold risk of death,17,52 and three-
Table 2 Symptoms and European Heart Rhythm Associa-
tion (EHRA) score of atrial fibrillation in Taiwanese versus
non-Taiwanese.
Taiwanese Non-
Taiwanese
p
Symptoms (%)
Palpitation 28.2 34.2 < 0.001
Dyspnea 25.1 40.5 < 0.001
Fatigue 16.3 36.9 < 0.001
Lightheadedness/
dizziness
19.5 15.0 0.001
Cheat pain 14.2 15.4 0.361
Syncope 1.9 1.9 0.992
 1 symptom 55.3 61.1 0.002
EHRA score (%)
I 18.5 23.9 < 0.001
II 69.5 50.5
III 11.2 20.8
IV 0.8 2.0
IIeIV 81.5 73.3 < 0.001
Recommendation
 Patterns of AF: paroxysmal, persistent, long-
standing persistent, and permanent, should be
documented for AF patients.
Table 3 Classification of atrial fibrillation (AF).
Paroxysmal AF 1. Recurrent AF that terminate
spontaneously within 7 d
2. AF of  48 h duration that are
terminated by electrical or
pharmacologic cardioversion
Persistent AF 1. A continuous AF that is sustained
more than 7 d
2. AF in which a decision is made
to electrically or pharmacologically
cardiovert the patient after  48 h
of AF, but prior to 7 days, should be
classified as persistent AF
Longstanding
persistent AF
A continuous AF that is
sustained > 12 mo
Permanent AF A condition of continuous AF rhythm
was accepted by patient and physician,
and a decision of ceasing further
attempts to restore and/or maintain
sinus rhythm was made by physician
and patients
2016 AF Guidelines of THRS/TSOC 899to four-fold risk of stroke,17,53e55 compared with those
without. In a recent cohort study of nonpermanent AF, the
annual risk of CV events was 17.7%, including CV death, MI,
stroke and TIA, CV admissions, and CV procedures.56
5. Symptoms
AF patients may present with varying symptoms. Besides
palpitation, dyspnea and fatigue were not uncommon.32 In
a recent global AF survey, the symptomatology of Taiwa-
nese was compared with that in non-Taiwanese (Table 2).30
It seems that, during the week prior to outpatient visit,
palpitation, dyspnea, and fatigue were more common in
non-Taiwanese, and lightheadedness/dizziness was more
common in Taiwanese. Overall, 61.1% of non-Taiwanese
complained of at least one symptom, more than that in
Taiwanese (55.3%, p Z 0.002). When the European Heart
Rhythm Association (EHRA) AF cardiac symptom classifica-
tion score was compared in both groups,57 Taiwanese had
81.5% of patients with an EHRA score II-IV, more than that in
non-Taiwanese (73.3%, p < 0.001).30 These data suggest
that majority of AF patients were very symptomatic, both
in Taiwan and in the world.
In a report of quality of life in patients with intermittent
AF,58 AF patients were either significantly worse or as
impaired as either PTCA or post-MI patients on all domains
of the SF-36.59 Similarly, AF was associated with modestly
impaired quality of life in Taiwanese patients,30 measured
by EQ-5D visual analogue scale.60Recommendation
 In patients with AF, a record of symptoms, including
palpitation, dyspnea, fatigue, chest pain, light-
headedness/dizziness, and an EHRA symptom score
should be obtained.6. Classifications
A variety of classification schemes for AF have been pro-
posed.61,62 A pattern-based classification scheme for AF,63
as shown in Table 3, is simple, and correlated well with
degree of atrial remodeling.64 Based on this classification,
paroxysmal AF was defined as recurrent AF (> 2 episodes)
that terminates spontaneously within 7 days. Persistent AF
was defined as recurrent AF that has sustained for more
than 7 days. Patients with continuous AF who undergo
cardioversion within 7 days is classified as either parox-
ysmal AF if the cardioversion is performed within 48 hours
of AF onset, or persistent AF if cardioversion is performed
more than 48 hours after onset of AF. Continuous AF with
duration > 1 year is defined as longstanding persistent AF.
Permanent AF is defined as condition of continuous AF that
is accepted by patient and physician and further attempts
to restore and/or maintain sinus rhythm are no longer
considered.7. Diagnosis and evaluation
A comprehensive clinical evaluation of a patient with AF
consists of a detailed history, a thorough physical examina-
tion, and diagnostic investigations. Table 4 shows a summary
of diagnosis and evaluation of AF. This table is useful for
assessing the severity of AF-related symptoms, identifying
the potential etiology of AF, classifying the type of AF,
Table 4 Diagnosis and evaluation in patients with atrial fibrillation (AF).
Basic evaluation
1. History and physical examination Symptoms associated with AF
AF type (paroxysmal, persistent, long persistent or permanent)
Date of the first symptomatic AF and total history of AF (y or mo)
Frequency, duration, precipitating/relieving factors, and modes
of initiation or termination of AF
Pharmacological or nonpharmacological responses
Comorbidities or reversible conditions (e.g., hyperthyroidism
or alcohol consumption)
2. 12-lead Electrocardiography Rhythm (confirm AF diagnosis)
Left ventricular hypertrophy
P-wave duration and morphology or fibrillatory P waves
WolffeParkinsoneWhite syndrome
Bundle-branch block
Old myocardial infarction
Other atrial or ventricular arrhythmias
Changes of the R-R, QRS duration, and QT intervals after
antiarrhythmic drug therapy
3. Transthoracic echocardiography Valvular heart disease
Left atrial and right atrial size
Left ventricular and right ventricular size and function
Estimated peak pulmonary artery systolic pressure
Left ventricular hypertrophy
Left atrial cavity/appendage thrombus
Pericardial diseases
4. Blood tests of thyroid,
renal, and hepatic function
At the first diagnosis of AF
When the ventricular rate is difficult to control or suspected
antiarrhythmic drugs-related adverse effects
Advanced evaluation (1 or several tests may be necessary)
1. 6-min walk test To evaluate the adequacy of rate control
To reproduce exercise-induced AF
To exclude myocardial ischemia prior to treatment with
a type IC antiarrhythmic drug a
2. Exercise testing To evaluate the adequacy of rate control
To reproduce exercise-induced AF
To exclude myocardial ischemia prior to treatment with
a type IC antiarrhythmic drug a
3. Holter or event monitoring To enhance AF diagnostic rate
To evaluate the adequacy of rate control
4. Transesophageal echocardiography To identify spontaneous echo contrast in atria
To identify left atrial cavity or appendage thrombus
To guide cardioversion
5. Electrophysiological study To confirm the mechanism of wide QRS-complex tachycardia
To identify and ablate a triggering arrhythmias such as atrial
flutter or paroxysmal supraventricular tachycardia
To perform atrioventricular junction ablation for ventricular rate control
6. Chest radiograph To assess coexistent pulmonary diseases
To evaluate cardiac size and presence or absence of pulmonary hypertension
a Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs.
900 C.-E. Chiang et al.predicting prognosis, and choosing therapeutic strategies for
rhythm management and thromboembolism prevention.
7.1. History and physical examination
Symptoms associated with AF including palpitations, dys-
pnea, dizziness, weakness, and chest pain are highly vari-
able.65 Although some AF patients may present debilitatingsymptoms, others may follow an asymptomatic period of
unknown duration. The impact of these symptoms on
quality of life can be evaluated by the EHRA symptom
score,66 which only includes symptoms that are attributable
to AF and reversed or attenuated by restoring sinus rhythm
or achieving effective rate control.
The physical findings suggestive of AF consist of an
irregularly irregular arterial pulse, an irregular jugular
Recommendation
 In patients aged  65 years, opportunistic screening
by pulse palpation, followed by ECG in those with an
irregular pulse, is indicated to detect AF prior to the
first stroke.
2016 AF Guidelines of THRS/TSOC 901venous pulse without a-wave, and variation in the intensity
of the first heart sound. The physical examination may also
uncover the underlying etiology of AF or comorbidities
including hypertension, heart failure, valvular heart dis-
ease, congenital heart disease, or hyperthyroidism.
7.2. Diagnostic investigations
The diagnosis of AF is established by electrocardiography
(ECG) showing at least a single-lead recording
for  30 seconds during the arrhythmic event.66 AF is
defined by the following ECG characteristics: (1) the sur-
face ECG showing irregularly irregular R-R intervals; (2)
there are no distinct P waves on the surface ECG (some
regular atrial activity may be seen in several ECG leads,
particularly in lead V1); and (3) the interval between two
consecutive atrial activations when discernible is usually
variable and >300 beats/min (bpm). In patients with
implanted pacemakers or defibrillators, AF can be detected
automatically via the diagnostic and memory functions of
the device.67 In patients with suspected AF, a 12-lead ECG
is recommended as the first step to establish the diagnosis.
Clinical symptoms highly suggestive of AF or other ar-
rhythmias, but not detected by a 12-lead ECG, ECG moni-
toring is need.
Intermittent ECG monitoring devices include Holter
(24 hours to 7 days) recording, patient and automatically
activated event-recorder, and external loop recorders.
Kirchhof et al66 reported that extending the duration of
Holter recording for 24 hours to 7 days or using daily and
symptom-activated event recordings may increase the
diagnosis rate to 70% in AF patients, with a negative pre-
dictive value of 30e50%. An external loop recorder is ideal
for capturing brief episodes of arrhythmias not possibly
detected by other devices. The external loop recording is
triggered automatically according to the implemented
arrhythmia detection algorithm or triggered manually by
the patient. This device is suitable for highly motivated
patients to detect AF within a limited period of time,
usually 1e4 weeks.68
Continuous ECG monitoring can be obtained from
implantable devices capable of recording intracardiac
atrial electrograms such as dual-chamber pacemakers and
defibrillators, which can detect AF appropriately, particu-
larly when an arrhythmia is  5 minutes in duration.57
Another approach is to use a leadless implantable loop
recorder, which can provide continuous AF monitoring over
a 2-year period with automatic AF detection algorithm
based on analyzing R-R interval regularity. The clinical data
suggest that use of implantable loop recorder has a good
sensitivity but less specificity for AF detection. Recently,
new devices incorporating wireless, ambulatory, real-time
transmission technologies with a built-in auto-detection
system have been used to facilitate the diagnosis of AF.69,70
With continuous technological improvement for both soft-
ware and hardware designs,71 we can anticipate that the
future device is able to detect AF accurately in a timely
manner to allow early therapeutic interventions to prevent
and treat AF-related complications.
Since exploring underlying etiology and the associated
comorbidities is necessary for making appropriate decisions
regarding the use of rate- and rhythm-controlling agentsand antithrombotic therapy, a variety of routine in-
vestigations are warranted in all patients presenting with a
history of AF.72,73 A chest radiograph is valuable in evalu-
ating pulmonary diseases and the pulmonary vasculature. It
is important that thyroid, renal, and hepatic functions,
serum electrolytes, and the blood profile with coagulation
study should be measured at least once in the course of
evaluation. All patients with AF should also undergo two-
dimensional and Doppler ECG to assess left atrial (LA) and
left ventricular (LV) dimensions and functions and to detect
valvular, congenital, and pericardial disease or cardiomy-
opathy. Thrombus in the LA or LA appendage (LAA) is often
detected with transesophageal ECG (TEE). Previous data
showed that thrombus, spontaneous echo contrast,
reduced LAA flow velocity, and aortic atheroma are
important risk factors associated with thromboembolism in
patients with nonvalvular AF.74 Therefore, detection of LA
and/or LAA thrombus in the setting of stroke or systemic
embolism is highly suggestive of a cardiogenic mechanism.
Additional investigations include exercise testing and
invasive electrophysiological studies, which may be
considered in specific conditions. For example, exercise
testing may supplement Holter monitoring in some patients
with exercise-related symptoms and help to determine the
ventricular rate during exercise after adopting rate control
strategy. Invasive electrophysiological studies and radio-
frequency catheter ablation should be considered in AF
patients with suspected coexistent atrial flutter (AFL) or
paroxysmal supraventricular tachycardia.8. Management algorithm
The overall management algorithm is shown in Figure 2.
When encountering patients with AF, hemodynamic status
should be checked immediately. In the case of hemody-
namically instability, including hypotension, shock, dys-
pnea, chest tightness, or acute coronary syndrome (ACS),
electrical cardioversion (EC; Section 12.1) with concomi-
tant heparin infusion should be undertaken immediately. If
there is no evidence of hemodynamic instability, the risk of
stroke should be assessed and a documented strategy for
stroke prevention should be provided (Section 9). Symp-
toms should be re-assessed thereafter, and acute rate
control (Section 11.1) is advocated if symptoms persist.
Otherwise, patients can choose EC (Section 12.1). In pa-
tients who do not have symptoms or whose symptoms have
been resolved by acute rate control strategy (Section 11.1),
subsequent management would depend on type of AF.
For patients with paroxysmal AF, several options are
provided, depending on AF burden or frequency of AF. For
patients with low AF burden, patients may choose to have
Hemodynamic instability
Electrical CV*Stroke prevenƟon
Diagnosis of AF
No Yes
Symptoms
Acute rate control
Yes
Paroxysmal AF
No
Symptoms resolved
Persistent AF Permanent AF
Electrical or pharmacological CV
Sinus rhythm Chronic rate control
Chronic rhythm controlAF ablaƟon
Failed or symptomaƟc
Low burden High burden
Chronic rhythm control
ObservaƟon or
“Pill-in-the-pocket”
Yes
NoNo
Figure 2 Overall management algorithm of atrial fibrillation. AF Z atrial fibrillation; CV Z cardioversion.
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Figure 3 Annual risk of stroke in Taiwanese and Swedish.
902 C.-E. Chiang et al.AF ablation (Section 13), or to be merely observed clini-
cally. “Pill-in-the-pocket” strategy (Section 12.4) can be
taken if patients have infrequent, but symptomatic,
recurrence of AF. If patients have high AF burden, they can
choose AF ablation (Section 13) or chronic rhythm control
(Section 12.3).
For patients with persistent AF (including longstanding
persistent AF), patients can choose to have a chronic rate-
control strategy (Section 11.2), EC (Section 12.1), or phar-
macological cardioversion (Section 12.2). If sinus rhythm is
restored, patients can be maintained on a chronic rhythm-
control strategy (Section12.3), or choose to have AF abla-
tion (Section 13). If sinus rhythm cannot be obtained, pa-
tients can choose to have a chronic rate-control strategy
(Section 11.2), or to have AF ablation (Section 13). If sinus
rhythm cannot be maintained by chronic rhythm-control
strategy, nor by AF ablation, or patients are still symp-
tomatic, a chronic rate-control strategy (Section 11.2)
should be undertaken.
For patients with permanent AF, therapeutic choice
become simpler. A chronic rate control strategy (Section
11.2) and stroke prevention (Section 9) is suggested.
It is important to take stroke prevention measures at
every step of therapeutic courses, irrespective of AF type.
9. Stroke prevention
9.1. Atrial fibrillation-associated stroke in Taiwan
In Asia, AF patients had three- to four-fold risk of stroke
compared with patients without AF.17,53e55 The annual risk
of AF-associated stroke in Taiwan has recently been
explored.75 Using the National Health Insurance ResearchDatabase (NHIRD; 1996e2011) of the whole Taiwanese
population, Chao et al75 studied the annual risk of stroke of
185,570 AF patients who did not receive any antiplatelet or
oral anticoagulant (OAC). Figure 3 shows the annual risk of
stroke in Taiwanese and in a recent Swedish cohort,76 ac-
cording to the CHA2DS2-VASc score [Congestive heart fail-
ure, Hypertension, Age  75 years (doubled), Diabetes,
Stroke (doubled)eVascular disease, Age 65e74 years, Sex
category (female)].77,78 The risk of stroke was numerically
higher in Taiwanese than in Swedish patients, at CHA2DS2-
VASc scores 0e4. These risks were higher than those from a
previous report by Lin et al79 from Taiwan. Both used NHIRD
AF population who were not exposed to any antiplatelet or
Figure 4 The annual risk of stroke/systemic embolization events in Asians versus non-Asians under either warfarin or non-vitamin
K antagonist oral anticoagulant treatment in four major clinical trials. A: RE-LY trial; B: ROCKET AF trial; C: ARISTOTLE trial; D:
ENGAGE AF trial. (Modified from Chiang et al.95 with permission.)
Table 5 CHADS2 and CHA2DS2-VASc score.
CHADS2 CHA2DS2-
VASc
Congestive heart failure 1 1
Hypertension 1 1
Age  75 y 1 2
Diabetes mellitus 1 1
Stroke/TIA 2 2
Vascular disease (prior MI,
PAD, or aortic plaque)
0 1
Age 65e74 y 0 1
Sex category (i.e., female sex) 0 1
Maximum score 6 9
MI Z myocardial infarction; PAD Z peripheral artery disease;
TIA Z transient ischemic attack.
2016 AF Guidelines of THRS/TSOC 903OAC, but only 7920 AF patients from a 1-million population
database were analyzed in Lin et al’s79 report. Instead,
Chao et al’s75 report took the whole AF population, which
included 186,570 AF patients. In parallel to Chao et al’s75
observation, Chang et al80 showed a four-fold higher
stroke risk in AF patients with a CHA2DS2-VASc score of 0 in
men and 1 in women compared to the non-AF controls using
the NHIRD.
It is difficult to know the risk of AF-associated stroke in
drug-naive patients from randomized controlled trials
(RCTs), because all patients have to be treated with some
forms of OACs due to ethical reasons. It would be possible,
however, to examine the risk of stroke whilst taking OAC
treatment for Asians versus non-Asians. Four large scaled
RCTs (the RE-LY trial, the ROCKET AF trial, the ARISTOTLE
trial, and the ENGAGE AF trial) have been done to compare
warfarin versus NOACs (previously referred to as new or
novel OACs).81e84 The data for Asians versus non-Asians
from these four RCTs have also been published.85e88 The
mean CHADS2 [Congestive heart failure, Hypertension,
Age  75 years, Diabetes, Stroke (doubled)]89 scores were
very similar among Asians versus non-Asians in each trial
(2.2 vs. 2.1 in the RE-LY trial, 3.2 vs. 3.5 in the ROCKET AF
trial, 2.1 vs. 2.1 in the ARISTOTLE trial, and 2.9 vs. 2.8 in
the ENGAGE AF trial). The annual risk of stroke/systemic
embolization events (SEEs) was generally higher in Asians
than in non-Asians, whether on warfarin or on NOAC
treatment (Figure 4).
The information regarding stroke prevention in this
guideline is applied to nonvalvular AF. Patients with mod-
erate or severe rheumatic mitral stenosis or with implan-
tation of mechanical prosthetic valve were not included.Otherwise, patients with mitral or tricuspid insufficiency,
and aortic stenosis or insufficiency, can be evaluated and
treated according to this guideline.
9.2. CHADS2 and CHA2DS2-VASc scores
The CHADS2 score has been used to predict annual stroke
risk in patients with nonvalvular AF for more than a decade
(Table 5).89 The CHADS2 score has various limitations,
90
being derived from the historical trial cohorts that only
randomized < 10% of patients screened, and many stroke
risk factors were not recorded nor consistently defined.
Many patients classified as low-risk using CHADS2
Recommendations
 The CHA2DS2-VASc score is recommended to assess
stroke risk in nonvalvular AF.
 In patients with a ‘low risk’ CHA2DS2-VASc score (i.e.
0 in males or 1 in females), no antithrombotic
therapy is recommended.
 In patients with a CHA2DS2-VASc score  1 (beyond
female sex alone), antithrombotic therapy should be
considered and NOACs are preferred over vitamin K
antagonist (VKA).
904 C.-E. Chiang et al.(score Z 0) have stroke rates > 1.5%/year, and a CHADS2
score of 0 does not reliably identify AF patients who are
truly low-risk.
More recently, the CHA2DS2-VASc score
77 has been rec-
ommended for stroke risk assessment (Table 5), by the
latest major guidelines from the European Society of Car-
diology (ESC),78 AsiaePacific Heart Rhythm Society,91
American Heart Association/American College of Cardiol-
ogy/Heart Rhythm Society,92 and the National Institute for
Health and Care Excellence.93 The CHA2DS2-VASc score is
more inclusive of common stroke risk factors in AF, and
performs best at initially identifying the low-risk AF pa-
tients (i.e. CHA2DS2-VASc score Z 0 in men, score Z 1 in
women) who do not need any antithrombotic
therapy.77,90,94e97 Of note, the CHA2DS2-VASc scoring sys-
tem has been validated and compared with standard
CHADS2 criteria in three recent studies from Chinese pa-
tients. The first study by Guo et al35 from China using a
hospital-based database suggested a similar stroke risk in
nonanticoagulated Chinese AF patients compared to Cau-
casians. In this study, the c-statistics for predicting stroke/
thromboembolism with CHADS2 and CHA2DS2-VASc were
0.58 (p Z 0.109) and 0.72 (p < 0.001), respectively.
Compared to CHADS2, the use of CHA2DS2-VASc would result
in a net reclassification improvement of 16.6% (p Z 0.009)
and an integrated discrimination improvement of 1.1%
(p Z 0.002). The CHA2DS2-VASc score performed better
than CHADS2 in predicting stroke/thromboembolism in this
Chinese AF population.35 The second study by Siu et al37
from Hong Kong have showed that the CHA2DS2-VASc
score is superior to the CHADS2 score in terms of stroke risk
stratification in 9727 Chinese with AF. The adjusted net
clinical benefit favored warfarin over aspirin or no therapy
for almost all Chinese AF patients CHA2DS2-VASc score  1.
The third study is the most robust.75 Chao et al75 used
the NHIRD in Taiwan. A total of 186,570 AF patients without
antithrombotic therapy were selected as the study cohort.
The clinical endpoint was the occurrence of ischemic
stroke. During a mean follow-up of 3.4 years, 23,723 pa-
tients (12.7%) experienced ischemic stroke. The CHA2DS2-
VASc score was compared to the ATRIA score.98 The
CHA2DS2-VASc score performed better than ATRIA score in
predicting ischemic stroke as assessed by c-indexes (0.698
vs. 0.627, respectively; p < 0.0001). The CHA2DS2-VASc
score also improved the net reclassification index by 11.7%
compared with ATRIA score (p < 0.0001). Among 73,242
patients categorized as low-risk on the basis of an ATRIA
score of 0e5, the CHA2DS2-VASc scores ranged from 0 to 7,
and annual stroke rates ranged from 1.06% to 13.33% at 1-
year follow-up and from 1.15% to 8.00% at 15-year follow-
up. The c-index of CHA2DS2-VASc score (0.629) was signifi-
cantly higher than that of the ATRIA score (0.593) in this
low-risk category (p < 0.0001). Chao et al75 concluded that
patients categorized as low-risk by use of the ATRIA score
were not necessarily low-risk, and the annual stroke rates
can be as high as 2.95% at 1-year follow-up and 2.84% at 15-
year follow-up. In contrast, patients with a CHA2DS2-VASc
score of 0 had a truly low risk of ischemic stroke, with an
annual stroke rate of approximately 1%.75
The age threshold set in the CHA2DS2-VASc score is
65 years. The risk of stroke in Asians is generally higher than
that in Caucasians.99 Therefore the age threshold for AFpatients in Asia might be different than that in Caucasians.
Recently, Chao et al100 used the NHIRD in Taiwan to study
186,570 nonanticoagulated AF patients. There were 9416
men with a CHA2DS2-VASc score of 0 and 6390 women with a
CHA2DS2-VASc score of 1. Their risk of ischemic stroke was
analyzed with stratification on the basis of age. They found
that the annual risks of ischemic stroke for men (score 0)
and women (score 1) were 1.15% and 1.12%, respectively,
and continuously increased from younger to older age
groups, with an increment in stroke risk evident for patients
older than 50 years. At a cutoff of 50 years, patients could
be further stratified into two subgroups with different
stroke risks (age  50 years: 1.78%/y; vs. < 50 years: 0.53%/
y). This observation was consistent for men (1.95%/y vs.
0.46%/y, respectively) and women (1.58%/y vs. 0.64%/y,
respectively) with AF. They concluded that for Taiwanese
patients aged 50e64 years, the annual stroke risk was
1.78%, which may exceed the threshold for OAC use for
stroke prevention. The annual risk of ischemic stroke for AF
patients younger than 50 years was 0.53%, which was truly
low-risk, and OACs could be omitted. Whether resetting the
age threshold to 50 years could refine current clinical risk
stratification for Asian AF patients deserves further
study.100
Since the CHA2DS2-VASc score has outperformed other
clinical scoring systems in predicting AF-associated stroke,
the TSOC/THRS AF guidelines strongly recommend the use
of this score. Both cardiologists and general practitioners
should be encouraged to use the CHA2DS2-VASc score as a
basic risk assessment method for selecting better anti-
coagulation therapy.9.3. HAS-BLED score
The effect of OAC in reducing stroke should be balanced by
the bleeding risk, especially intracranial hemorrhage (ICH),
with the use of OAC. Many risk factors for bleeding are also
risk factors for stroke. While bleeding risk correlates with
stroke risk scores (e.g. CHADS2, CHA2DS2-VASc), specific
bleeding risk scores may perform better than stroke risk
scores for predicting bleeding. Various risk scores for pre-
dicting bleeding in AF have been proposed,101,102 but, until
recently, uptake has been poor due to their complexity.
More recently, the HAS-BLED [Hypertension, Abnormal
renal/liver function, Stroke, Bleeding history or predispo-
sition, Labile international normalized ratio (INR), Elderly,
Drugs/alcohol concomitantly] score has been proposed as a
Table 6 HAS-BLED score.
Clinical characteristics Definition Score
Hypertension SBP > 160 mmHg 1
Abnormal renal and liver
function (1 score each)
Renal: dialysis, transplantation, or creatinine  2.3 mg/dL
Liver: chronic hepatitis, cirrhosis, bilirubin > 2 ULN, with ALT > 3 ULN
1 or 2
Stroke Previous history, particularly lacunar 1
Bleeding Bleeding tendency or predisposition (e.g. anemia, recent GI bleed, etc.) 1
Labile INRs Unstable/high INR, or TTR <60% 1
Elderly Age > 65 y, frail condition 1
Drugs or alcohol (1 score each) Drugs: antiplatelet, NSAID
Alcohol excess
1 or 2
Maximum score 9
ALTZ alanine transaminase; CrZ creatinine; GIZ gastrointestinal; INRZ international normalized ratio; NSAIDZ nonsteroidal anti-
inflammatory drugs; SBP Z systolic blood pressure; TTR Z time in therapeutic range; ULN Z upper limit of normal.
2016 AF Guidelines of THRS/TSOC 905simple clinical score to predict clinically relevant bleeding
in AF patients (Table 6).103,104 HAS-BLED outperformed all
other bleeding risk scores.76,105,106 Of note, the HAS-BLED
score is the only score predictive of ICH105 and has also
been validated in Asian cohorts.35,97,107,108 The HAS-BLED
score has been recommended by the major AF guidelines
from the ESC, Canadian Cardiovascular Society and National
Institute for Health and Care Excellence.78,93,109
The HAS-BLED score has to be used appropriately. A high
score is not an excuse to withhold OAC (as such patients
derive an even greater net clinical benefit from OAC
treatment),76,94 but to flag up patients potentially at risk
for bleeding for more careful review and follow-up, and to
guide the use of appropriate OAC doses. Furthermore, the
HAS-BLED score for an AF patient is not static, but dynamic.
It is useful for clinicians to think about the correctable risk
factors for bleeding, such as uncontrolled hypertension (the
H in HAS-BLED), labile INRs (L), only applies on a VKA (pa-
tient), concomitant drugs such as aspirin or nonsteroidal
anti-inflammatory drugs, or alcohol excess/abuse (the D in
HAS-BLED).Recommendations
 The HAS-BLED score is recommended to assess
bleeding risk in nonvalvular AF.
 A HAS-BLED score  3 indicates high bleeding risk.
Some caution and regular follow-up of these patients
is needed.
 The HAS-BLED score is dynamic and some risk factors
are modifiable, such as uncontrolled hypertension,
labile INRs, concomitant drugs such as aspirin or
nonsteroidal anti-inflammatory drugs or alcohol
excess/abuse.
 The HAS-BLED score should not be used on its own to
exclude patients from OAC therapy.9.4. Role of aspirin
In a meta-analysis of seven trials comprising 3990 AF pa-
tients comparing aspirin versus placebo or no treatment,there was a nonsignificant 19% reduction in stroke inci-
dence.110 This 19% reduction was driven by the one single
positive trial (SPAF-1) which had major internal heteroge-
neity for the aspirin effect against placebo/control,
reducing stroke by 94% in anticoagulation-eligible patients
and by only 8% in anticoagulation-ineligible patients.111 The
SPAF-1 trial used aspirin 325 mg daily and had been stopped
early hence possibly exaggerating the aspirin efficacy re-
sults. Also, aspirin did not reduce strokes in those aged >
75 years, nor did it prevent severe strokes.111
Data on the efficacy and safety of aspirin in Asian pa-
tients with AF are similarly scarce. In a Japanese trial,
aspirin was compared with placebo in the stroke prevention
in low-risk AF patients.112 While there was no effect with
the use of aspirin in reducing stroke, the risk of bleeding
was increased by aspirin.112 In a recent Hong Kong cohort,
aspirin had a nonsignificant 18.7% reduction in ischemic
strokes, compared with no therapy.37 The overall annual
ICH incidence in this Hong Kong cohort, who did not receive
antithrombotic therapy, was 0.5% per year, comparable to
published rates in Caucasian AF patients (0.6% per year).113
The rate of ICH increased to 0.77% per year among Hong
Kong patients receiving aspirin.37 This number was higher
than that from Caucasians (aspirin 0.6% per year).113
The risks of ischemic stroke and ICH in a real-world
cohort of Chinese AF patients receiving aspirin or other
therapy were reported recently from Hong Kong.114 The
incidence of ischemic stroke on aspirin was 7.95%/y, higher
than dabigatran (110 mg) users. The incidence of ICH was
lower in dabigatran (110 mg) users (0.32%/y) compared
with those on aspirin (0.80%/y).114 Similarly, In the AVER-
ROES trial, the risk of stroke was significantly lower in
apixaban group than in aspirin group (relative risk reduction
45%, p < 0.001).115 The risk of ICH was numerically lower in
the apixaban group.115 These data suggest that there is no
role for using aspirin in stroke prevention.
Despite a paucity of data to support the use of aspirin in
the stroke prevention in AF, the use of aspirin is highly
prevalent in many Asian countries.41,116 Based on the NHIRD
of Taiwan between 2003 and 2004, 70.3% of the AF patients
were categorized as high risk group for stroke,117 according
to 2011 American College of Cardiology/American Heart
Association recommendations.118 Among them, 50.6%
received aspirin and 15.4% received warfarin. A latest study
Table 7 SAMe-TT2R2 score.
Acronym Definition Points
S Sex (female) 1
A Age (< 60 y) 1
M Medical history a 1
e
T Treatment (interacting drugs, e.g.,
amiodarone for rhythm control)
1
T Tobacco use (within 2 years) 2
R Race (nonwhite) 2
Maximum
points
8
a More than two of the following: hypertension, diabetes,
coronary heart disease/myocardial infarction, peripheral artery
disease, congestive heart failure, stroke, pulmonary disease,
and hepatic or renal disease.
906 C.-E. Chiang et al.using Taiwan NHIRD between 2001 and 2008 showed that
the percentage of AF patients who received warfarin,
aspirin, or no treatment in Taiwan was 16%, 62%, and 22%,
respectively.119
Dual antiplatelet therapy including aspirin plus clopi-
dogrel has been tested in the ACTIVE-W and ACTIVE-A tri-
als.120,121 In the ACTIVE-W trial, aspirin plus clopidogrel was
compared with warfarin, and the trial was prematurely
terminated due to a 40% reduction (p < 0.001) in stroke by
warfarin.120 In the ACTIVE-A trial, aspirin plus clopidogrel
was compared to aspirin along. The combination of aspirin
and clopidogrel resulted in a 28% risk reduction (p < 0.0002)
in strokes compared with aspirin alone, but increased major
bleeding by 57% (p < 0.001).121 For stroke prevention in AF,
it is widely accepted that warfarin is better than aspirin
plus clopidogrel, and aspirin plus clopidogrel is better than
aspirin alone. The latter benefits are dampened by the
significant increase in major bleeding events.92Recommendations
 Aspirin has no role in stroke prevention in patients
with nonvalvular AF.
 Dual antiplatelet therapy (DAPT) of aspirin and clo-
pidogrel has no role in the stroke prevention in pa-
tients with nonvalvular AF, unless under other
therapeutic indications, such as in patients with ACS
and receiving stenting therapy.9.5. Role of vitamin-K antagonists (VKA)
Warfarin is a VKA, inhibiting the formation of factor II, VII,
IX, and X in the coagulation cascades. In a meta-analysis of
six trials including of 2900 patients, comparing adjusted-
dose warfarin versus placebo or no treatment, warfarin
significantly reduced stroke by 64%, and total mortality by
26%.110 When adjusted-dose warfarin were compared with
aspirin in a meta-analysis of eight trials of 3647 patients,
warfarin reduced risk of stroke by 38%.110 In the BAFTA trial
evaluating the effect of warfarin versus aspirin on the
stroke prevention among high-risk elderly patients,
warfarin was superior in preventing stroke without a sig-
nificant increase in bleeding risk.122 Before the availability
of NOACs, warfarin was the treatment of choice for the
stroke prevention in AF.
The main problem in the use of warfarin lies in its narrow
therapeutic range. An INR of 2.0e3.0 was the optimal range
of warfarin use for Caucasians.123,124 The average individual
time in the therapeutic range (TTR) needs to be above 65%
to achieve the best safety and efficacy endpoints.57 How-
ever, the TTR was at best 50% in clinic services in the USA,
although anticoagulation clinic services were associated
with somewhat better TTR compared with standard com-
munity care.125 The TTRs in warfarin users in Asian were
generally lower,36 being attributed to diet, herbal medi-
cines, etc.126,127 Lack of structured anticoagulation ser-
vices in many Asian countries may be an added logistic issue
that precludes effective VKA management.The recently developed SAMe-TT2R2 [Sex female,
Age < 60 years, Medical history (more than two comor-
bidities), Treatment (interacting medications, e.g.
amiodarone), Tobacco use (doubled), Race (doubled)]
score is useful in predicting those patients who would do
well on VKA with a high TTR of >70% (SAME-TT2R2 score
0e1) and those who would do less well (SAME-TT2R2
score  2; Table 7).128,129 This score has been validated
in Caucasians in predicting not only TTR,130 but also risk
of stroke/thromboembolism (TE), severe bleeding, and
death.131,132 Since nonwhite people would have a score of
at least 2, Asian patients are therefore less likely to have
a good TTR. In a recent report from Hong Kong, the SAMe-
TT2R2 score correlates well with TTR in Chinese AF pa-
tients, with a score > 2 having high sensitivity and
negative predictive values for poor TTR.133 Ischemic
stroke risk increased progressively with increasing SAMe-
TT2R2 score, consistent with poorer TTRs at high SAMe-
TT2R2 scores.
133
Warfarin has not been extensively tested against
placebo in large-scaled RCTs in Asians.134 In a recent
prospective cohort study in Hong Kong, warfarin reduced
stroke by 53%, compared with no treatment.37 The main
problem when using warfarin in Asians was the risk of
ICH. It has been shown that with a similar TTR level
Asians had four-fold increase in the risk of ICH,
compared with that in white people.135 Besides, the
mortality rate of ICH seems higher than that in white
people. In the recently reported data from Hong Kong,
the mortality rate of warfarin-induced ICH was 62%,136
higher than that in white people.137 The analysis of the
effect of warfarin versus NOACs in Asians are discussed in
Section 9.6.3.2.
Warfarin has been under-used in the stroke prevention
for AF in Taiwan, where only 15% of high risk groups
received warfarin.117 The under-use of warfarin is also
common in other Asian countries.36,41 Moreover, the TTR
was generally suboptimal in Asians. In a recent cohort
study, the TTRs for Asians including patients from India,
China, and other Southeast Asian countries were all below
40%.36 Thus, there remains a great unmet need for the
stroke prevention for AF in Asians.
Recommendations
 Warfarin has not been extensively tested against
placebo in large-scaled RCTs in Asians.
 The optimal therapeutic range of INR in the use of
warfarin has not been fully established in Asians,
although an INR 2.0e3.0 is recommended as the
optimal therapeutic range, with attention on the
average TTR; ideally >65%.
 The SAMe-TT2R2 score can be used to predict the
likelihood of achieving a high TTR (e.g. > 70%) in
warfarin users.
 In view of the difficulty in maintaining optimal TTR
and a significant increase in the risk of ICH, there
should be a higher priority to use NOACs rather than
warfarin for stroke prevention in Asian patients with
AF.
2016 AF Guidelines of THRS/TSOC 9079.6. Non-vitamin K antagonist oral anticoagulants
(NOACs)
The availability of NOACs (previously referred to as new or
novel OACs) has changed the landscape for stroke preven-
tion in AF.138,139 The four NOACsdthe oral direct thrombin
inhibitor, dabigatran, and the oral factor Xa inhibitors,
rivaroxaban, apixaban, and edoxabandhave predictable
pharmacokinetics, with a stable, dose-related anticoagu-
lant effect and few drug interactions, hence allowing fixed
dosing without the need for regular monitoring of anti-
coagulation status.140
9.6.1. Overview
The similarities and differences in the pharmacokinetics of
the four NOACs are shown in Table 8.78,141e143 The time to
maximal concentration and half-lives are generally similar
for all the four NOACs. The bioavailability is lowest for
dabigatran and highest for rivaroxaban. Also, rivaroxaban
must be taken with food as there is a 39% in the area under
the curve plasma concentrations to a very high bioavail-
ability of almost 100%, whilst there is no such issue for the
other NOACs. There are differences in the renal clearance
for different NOACs, with the highest for dabigatran (80%),
followed by edoxaban (50%), rivaroxaban (35%), andTable 8 Pharmacokinetic characteristics of non-vitamin K anta
Direct thrombin inhibitor
Dabigatran
Hours to Cmax 3
Half-life (h) 12e17
Bioavailability 6%
Absorption with food No effect
Intake with food recommended No
Renal clearance 80%
CYP metabolism None
Transporter P-glycoprotein
Modified from Camm et al,78 Heidbuchel et al,141 Eriksson et al,142 an
Cmax Z maximal concentration; CYP Z cytochrome P450.apixaban (27%). Drugedrug interaction through cytochrome
P (CYP) 450 is generally not an issue except for rivaroxaban
(66% CYP metabolism). All NOACs are excreted, in some
part, through P-glycoprotein (P-gp).
9.6.2. Clinical trials
The efficacy and safety of NOACs have been tested in four
major RCTs: the RE-LY trial, the ROCKET AF trial, the
ARISTOTLE trial, and the ENGAGE AF trial.81e84 Background
characteristics of the four major RCTs are shown in Table 9.
The RE-LY trial had a PROBE-design, while others were
double-blinded trials. All these trials compared NOACs with
dose-adjusted warfarin with target INR of 2.0e3.0, using
stroke plus SEEs as primary efficacy endpoints and for most
apart from ROCKET AF, major bleeding as the primary
safety endpoint. The inclusion criteria were based on
CHADS2 score.
The RE-LY trial included patients distributed equally
across stroke risk strata (CHADS2 score 0e1 in 31.9% of
patients, 2 in 35.6%, and > 2 in 32.5%). The ARISTOTLE trial
enrolled patients across stroke risk strata without CHADS2
score 0. Both the ROCKET AF trial and the ENGAGE AF trial
enrolled patients with higher risk (CHADS2 score  2), and
lower-risk patients (CHADS2 score Z 0 or 1) were not
included in these two trials. The mean CHADS2 scores were
2.1 for the RE-LY trial, 3.5 for the ROCKET trial, 2.1 for the
ARISTOTLE trial, and 2.8 for the ENGAGE AF trial. The mean
CHADS2 scores and distribution of patients in Asian sub-
group were similar to those in the global ones.
9.6.2.1. RE-LY trial. Dabigatran is a direct thrombin in-
hibitor, and was the first NOAC approved by the US Food
and Drug Administration (FDA) to reduce the risk of stroke
and SEEs in patients with nonvalvular AF. The efficacy and
safety of dabigatran was tested in the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy) trial,
which was an PROBE-designed trial comparing dabigatran
(150 mg or 110 mg twice daily in a blinded fashion) with
adjusted-dose warfarin (INR 2.0e3.0) in 18,113 patients
over a mean follow-up period of 2 years (Table 9).81 The
mean TTR for warfarin users was 64%. The primary
efficacy endpoint was stroke plus SEEs, and the primary
safety endpoint was major bleeding.
The efficacy and safety endpoints in the RE-LY trial are
shown in Table 10. The efficacy of dabigatran 150 mg twicegonist oral anticoagulants.
Direct factor Xa inhibitors
Rivaroxaban Apixaban Edoxaban
2e4 3 1e2
5e13 9e14 10e14
80% 60% 62%
þ39% No effect þ (6e22%)
Mandatory No No
35% 27% 50%
66% 15% <4%
P-glycoprotein P-glycoprotein P-glycoprotein
d Lip et al.143
Table 9 Background characteristics of four major randomized controlled trials.
RE-LY81,85 ROCKET AF82,86 ARISTOTLE83,87 ENGAGE AF84,88
Total patient
number
18,113 14,264 18,201 21,105
Asian patient no. 2782 932 1993 1943
Taiwan patient no. 355 159 57 234
Trial design PROBE Double-blind Double-blind Double-blind
Randomized groups Dose-adjusted warfarin
vs. blinded doses of
dabigatran (150 mg twice
daily, 110 mg twice daily)
Dose-adjusted
warfarin vs.
rivaroxaban
20 mg once daily
Dose-adjusted
warfarin vs. apixaban
5 mg twice daily
Dose-adjusted warfarin
vs. edoxaban (60 mg
once daily, 30 mg
once daily)
Mean age (y) 71.5 73 70 72
Mean follow-up (y) 2.0 1.9 1.8 2.8
Warfarin naı¨ve 50.4% 37.6% 43% 41%
Inclusion criteria
CHADS2  0  2  1  2
CHA2DS2-VASc  1  2  1  2
Global
CHADS2 (mean) 2.1 3.5 2.1 2.8
Proportions of patients by CHADS2 score
0 31.9% (0 or 1) 0% 0% 0%
1 0% 34.4% 0%
2 35.6% 13.0% 35.8% 77.4% (2 or 3)
3 32.5% (3e6) 43.6% 30.2% (3e6)
4 28.7% 22.6% (4e6)
5 12.7%
6 2.0%
Asians
CHADS2 (mean) 2.2 3.2 2.1 2.9
Proportions of patients by CHADS2 score
0 30.2% (0 or 1) 0% 0% 0%
1 0% 39.3% 0%
2 33.0% 24.0% 28.3% 76.5% (2 or 3)
3 36.8% (3e6) 42.2% 32.4% (3e6)
4 24.3% 23.5% (4e6)
5 8.3%
6 1.2%
CHADS2Z Congestive heart failure, Hypertension, Age  75 years, Diabetes, Stroke (doubled); CHA2DS2-VASc scoreZ Congestive heart
failure, Hypertension, Age  75 years (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65e74, Sex category (female);
PROBE Z prospective randomized opened-label blinded endpoint.
908 C.-E. Chiang et al.daily was superior to warfarin. There was a numerically
increased number of MI events amongst dabigatran-treated
patients, although absolute events were low (0.8%, 0.8%,
and 0.6% per year for patients randomized to dabigatran
150 mg twice daily, dabigatran 110 mg twice daily, and
warfarin, respectively).144 One meta-analysis of dabigatran
RCT found a statistically significant increase in the risk of
MI,145 but there was no signal of increased MI in a recent
report from FDA-sponsored Medicare analysis.146 Although
there was no difference in the primary safety endpoints for
dabigatran 150 mg twice daily dosing compared with
warfarin, the risk of ICH and major plus minor bleeding
were lower for dabigatran 150 mg twice daily dosing. There
is an increased risk of gastrointestinal bleeding with dabi-
gatran 150 mg twice daily, and this finding has been repli-
cated in the recent report from a Medicare database.146
For dabigatran 110 mg twice daily dosing, the efficacy
was generally similar to warfarin, except that the risk ofhemorrhagic stroke was lower for dabigatran (Table 10).
Dabigatran 110 mg twice daily dosing was safer than
warfarin in the risk of major bleeding, ICH, and major plus
minor bleeding.
This guideline does not recommend using dabigatran in
patients with a calculated creatinine clearance < 30 mL/
min, according to the exclusion criteria of the RE-LY trial.81
9.6.2.2. ROCKET AF trial. Rivaroxaban is an oral direct
factor Xa inhibitor, and is the second NOAC approved by
FDA for reduction of risk of stroke and SEE in patients with
nonvalvular AF. The ROCKET AF (The Rivaroxaban Once
Daily Oral Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism, for Prevention of Stroke and Em-
bolism Trial, in Atrial Fibrillation) trial is a double-blind
study, comparing rivaroxaban (20 mg/day; 15 mg/d in
patients with creatinine clearance 30e49 mL/min) with
dose-adjusted warfarin (INR 2.0e3.0) in 14,264 patients
Table 10 Relative risk reduction in the efficacy and safety endpoints of non-vitamin K antagonist oral anticoagulant (NOAC) versus warfarin in four major randomized controlled
trials (RCTs).
REeLY81 ROCKET AF82 ARISTOTLE83 ENGAGE AF84
Dabigatran 150 mg Dabigatran 110 mg Rivaroxaban Apixaban Edoxaban 60 mg Edoxaban 30 mg
RR p RR p RR p RR p RR p RR p
Efficacy endpoints
Stroke þ SEE 0.66 (0.53e0.82) < 0.001 0.91 (0.74e1.11) 0.34 0.88 (0.75e1.03) 0.12 0.79 (0.66e0.95) 0.01 0.87 (0.73e1.04) 0.08 1.13 (0.96e1.34) 0.10
Ischemic
stroke
0.76 (0.60e0.98) 0.03 1.11 (0.89e1.40) 0.35 0.94 (0.75e1.17) 0.58 0.92 (0.74e1.13) 0.42 1.00 (0.83e1.19) 0.97 1.41 (1.19e1.67) < 0.001
Hemorrhagic
stroke
0.26 (0.14e0.49) < 0.001 0.31 (0.17e0.56) < 0.001 0.59 (0.37e0.93) 0.024 0.51 (0.35e0.75) < 0.001 0.54 (0.38e0.77) < 0.001 0.33 (0.22e0.50) < 0.001
Myocardial
infarction
1.27a (0.94e1.71) 0.12 1.29a (0.96e1.75) 0.09 0.81 (0.63e1.06) 0.121 0.88 (0.66e1.17) 0.37 0.94 (0.74e1.19) 0.60 1.19 (0.95e1.49) 0.13
CV death 0.85 (0.72e0.99) 0.04 0.90 (0.77e1.06) 0.21 0.89 (0.73e1.10) 0.289 0.89 (0.76e1.04) NA 0.86 (0.77e0.97) 0.013 0.85 (0.76e0.96) 0.008
All-cause
death
0.88 (0.77e1.00) 0.051 0.91 (0.80e1.03) 0.13 0.85 (0.70e1.02) 0.073 0.89 (0.80e0.998) 0.047 0.92 (0.83e1.01) 0.08 0.87 (0.79e0.96) 0.006
Safety endpoints
Major
bleeding
0.93 (0.81e1.07) 0.31 0.80 (0.69e0.93) 0.003 1.04 (0.90e1.20) 0.58 0.69 (0.60e0.80) < 0.001 0.80 (0.71e0.91) < 0.001 0.47 (0.41e0.55) < 0.001
Intracranial
hemorrhage
0.40 (0.27e0.60) < 0.001 0.31 (0.20e0.47) < 0.001 0.67 (0.47e0.93) 0.02 0.42 (0.30e0.58) < 0.001 0.47 (0.34e0.63) < 0.001 0.30 (0.21e0.43) < 0.001
GI bleeding 1.50 (1.19e1.89) < 0.001 1.10 (0.86e1.41) 0.43 1.39 (1.19e1.61) NA 0.89 (0.90e1.15) 0.37 1.23 (1.02e1.50) 0.03 0.67 (0.53e0.83) < 0.001
Bleeding of
any cause
0.91b (0.86e0.97) 0.002 0.78b (0.74e0.83) < 0.001 1.03c(0.96e1.11) 0.44 0.71d (0.68e0.75) < 0.001 0.86c (0.80e0.92) < 0.001 0.62c (0.57e0.67) < 0.001
CV Z cardiovascular; GI Z gastrointestinal; NA Z not available; RR Z relative risk reduction; SEE Z systemic embolic event.
a Reference 144.
b Major þ minor bleeding.
c Major and nonmajor clinically relevant bleeding.
d Any bleeding.
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910 C.-E. Chiang et al.with AF and a prior history of stroke or at least two other
additional risk factors for stroke (Table 9). It is worth noting
that the patients enrolled in the ROCKET AF trial had a high
risk for stroke, with an average CHADS2 score of 3.5, higher
than other NOAC trials. The mean follow-up period was
1.9 years, and the mean TTR for warfarin users was
55%.82 The primary efficacy endpoint for the intention-to-
treat analysis was stroke plus SEE, and the primary safety
endpoint was major bleeding.82
The efficacy and safety endpoints in the ROCKET AF trial
are shown in Table 10. In general, rivaroxaban was non-
inferior to warfarin for the efficacy endpoints, but the risk
of hemorrhagic stroke was significantly lower than
warfarin.82 The risk of major bleeding was similar to
warfarin, but the risk of gastrointestinal bleeding was
increased. However, the risk of ICH was significantly
decreased, a consistent finding for all NOACs.82
This guideline does not recommend using rivaroxaban in
patientswith a calculated creatinine clearance<30mL/min,
according to the exclusion criteria of the ROCKET AF trial.82
9.6.2.3. AVERROES and ARISTOTLE trials. Apixaban is
another direct factor Xa inhibitor and is the third NOAC
approved by the FDA for reduction or risk of stroke and SEE
in patients with nonvalvular AF. The efficacy of apixaban
has been examined in two RCTs: ARISTOTLE and AVERROES.
In the AVERROES (Apixaban Versus Acetylsalicylic Acid to
Prevent Strokes) trial, 5599 patients with nonvalvular AF
and at least one additional stroke risk factor who were
unsuitable for VKA therapy were randomized to apixaban
5 mg twice daily or aspirin 81e324 mg once daily.115 A
reduced dose of apixaban 2.5 mg twice daily were used in
patients (9.1% in the apixaban group) with at least two of
the following criteria: age  80 years; body weight  60 kg;
and serum creatinine  1.5 mg/dL (6% in the apixaban
group). After a mean follow-up of 1.1 years, the trial was
stopped early because of a clear benefit in favor of apix-
aban.116 The primary outcome of stroke or SEE was 1.6%/y
in patients assigned to apixaban compared with 3.7%/y in
patients assigned to aspirin [hazard ratio (HR) 0.45; 95%
confidence interval (CI), 0.32e0.62; p < 0.001]. The rates
of major bleeding were similar with apixaban (1.4%/y) and
aspirin (1.2%/y; HR with apixaban, 1.13; 95% CI, 0.74e1.75;
p Z 0.57). The rates of ICH were numerically lower in the
apixaban group (HR with apixaban, 0.85; 95% CI, 0.38e1.90;
p Z 0.69). Importantly, the rates of gastrointestinal
bleeding were also identical (0.4% per year; HR with apix-
aban, 0.86; 95% CI, 0.40e1.86; p Z 0.71). The AVERROES
study concluded that in patients with AF for whom VKA was
unsuitable, apixaban reduced the risk of stroke or SEE
without significantly increasing the risk of major bleeding
or ICH.115
In the ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) trial,
18,201 patients with nonvalvular AF (excluding patients
with moderate/severe mitral stenosis or prosthetic heart
valve) and CHADS2 score  1 were randomized to apixaban
5 mg twice daily or adjusted-dose warfarin (Table 9).83 The
mean follow-up period was 1.8 years and the mean TTR was
62%. A reduced dose of apixaban 2.5 mg twice daily were
used in patients (9.1% in the apixaban group) with at least
two of the following criteria: age  80 years; bodyweight  60 kg; and serum creatinine  1.5 mg/dL (9.1% in
the apixaban group).
The efficacy and safety endpoints in the ARISTOTLE trial
are shown in Table 10. Among the efficacy endpoints,
apixaban was superior to warfarin in reducing the risk of
stroke/SEE, hemorrhagic stroke, and all-cause death.83 For
the safety endpoints, apixaban was better than warfarin in
the reduction of major bleeding, ICH, and any bleeding.
The ARISTOTLE trial concluded that, in patients with non-
valvular AF, apixaban was superior to warfarin in preventing
stroke/SEE, caused less bleeding, and resulted in lower
mortality.83
Based on new pharmacokinetic profiles in a limited data
set,147 the prescription recommendations of apixaban in
USA were changed to “the recommended dose for non-
valvular atrial fibrillation patients with end-stage renal
disease maintained on hemodialysis is 5 mg twice daily.
Reduce dose to 2.5 mg twice daily if one of the following
patient characteristics (age  80 years or body weight 6
0 kg) is present.” These recommendations represent the
use of full-dose apixaban in many patients undergoing
dialysis and are made with no evidence regarding the
clinical impact or safety of continued use of this agent.147
There are no published data for the use of apixaban in
these clinical settings. This guideline, therefore, does not
recommend using apixaban in patients with a calculated
creatinine clearance < 25 mL/min, according to the
exclusion criteria of the ARISTOTLE trial.83
9.6.2.4. ENGAGE AF trial. Edoxaban is a direct factor Xa
inhibitor and is the fourth NOAC approved by the FDA for
reduction or risk of stroke and SEE in patients with non-
valvular AF. In the ENGAGE AF-TIMI 48 (The Effective
Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation-Thrombolysis in Myocardial Infarction 48) trial,
21,105 patients with nonvalvular AF and a CHADS2 score  2
were randomized to two once-daily regimens of edoxaban
(60 mg and 30 mg) or adjusted-dose warfarin (Table 9).84
The mean follow-up period was 2.8 years and the mean
TTR was 65%.
The efficacy and safety endpoints in the ENGAGE trial
are shown in Table 10. The efficacy of edoxaban 60 mg once
daily was noninferior to warfarin, but the risk of hemor-
rhagic stroke and CV death was lower with edoxaban 60 mg
once daily. The safety endpoints generally favor the use of
edoxaban 60 mg once daily, except that the risk of
gastrointestinal bleeding was higher with edoxaban.
For edoxaban 30 mg once daily, albeit primary endpoints
did not show significant difference when compared with
warfarin, the risk of ischemic stroke was higher than
warfarin. Consistent to other NOACs, the risk of hemor-
rhagic stroke was lower with the use of edoxaban 30 mg.
Interestingly, CV death and all-cause death were lower for
edoxaban 30 mg. All the safety endpoints were in favor of
edoxaban 30 mg.
This guideline does not recommend using edoxaban in
patients with a calculated creatinine clearance < 30 mL/
min, according to the exclusion criteria of the ENGAGE AF
trial.84
9.6.2.5. Meta-analysis of major trials. The efficacy and
safety of four major RCTs of NOACs (the RE-LY trial, the
2016 AF Guidelines of THRS/TSOC 911ROCKET AF trial, the ARISTOTLE trial, and the ENGAGE AF
trial)81e84 were analyzed in a prespecified meta-analysis.139
There were 71,683 participants included, and the main
outcomes were stroke/SEEs, ischemic stroke, hemorrhagic
stroke, all-cause mortality, MI, major bleeding, ICH, and
gastrointestinal bleeding. Altogether, 42,411 participants
received a NOAC and 29,272 participants received
warfarin. Standard doses of NOACs (dabigatran 150 mg
twice daily, rivaroxaban 20 mg once daily, apixaban 5 mg
twice daily, and edoxaban 60 mg once daily) significantly
reduced stroke/SEEs by 19% compared with warfarin (risk
ratio 0.81,95% CI 0.73e0.91; p < 0.0001), mainly driven
by a reduction in hemorrhagic stroke (0.49, 0.38e0.64;
p < 0.0001). NOACs also significantly reduced all-cause
mortality (0.90, 0.85e0.95; p Z 0.0003) and ICH (0.48,
0.39e0.59; p < 0.0001), but increased gastrointestinal
bleeding (1.25, 1.01e1.55; p Z 0.04). There were no
heterogeneity for stroke/SEEs in important subgroups, but
there was a greater relative reduction in major bleeding
with NOACs when the center-based TTR was < 66% than
when it was  66% (0.69, 0.59e0.81 vs. 0.93, 0.76e1.13;
p for interaction 0.022). Low-dose NOAC regimens
(dabigatran 110 mg twice daily, and edoxaban 30 mg once
daily) showed similar overall reductions in stroke/SEEs to
warfarin (1.03, 0.84e1.27; p Z 0.74), but a significant
reduction in the risk of hemorrhagic stroke (0.33,
0.23e0.46; p < 0.0001) and ICH (0.31, 0.24e0.41;
p < 0.0001). However, there was a significantly increased
risk of ischemic stroke (1.28, 1.02e1.60; p Z 0.045) and
MI (1.25, 1.04e1.50; p Z 0.018).139
This meta-analysis is the first to include data for all four
NOACs studied in the pivotal phase 3 clinical trials for the
prevention of stroke/SEEs in patients with AF. NOACs had a
favorable riskebenefit profile, with significant reductions
in stroke, ICH, and mortality, and with similar major
bleeding as for warfarin, but increased gastrointestinal
bleeding. The relative efficacy and safety of NOACs wasTable 11 Risk profiles of atrial fibrillation in Asians versus non-
Heart failure
(%)
Hypertension
(%)
RE-LY85
Asians (n Z 2782) a 36.3 71.2
Non-Asians (n Z 15,331) 31.2 80.2
ROCKET AF86
East Asians (n Z 932)b 38.6 79.9
Non-East Asians (n Z 13,322) 64.1 91.3
ARISTOTLE87
Asians (n Z 1993)c 26.2 82.3
Non-Asians (n Z 16,202) 36.6 88.1
ENGAGE AF88
East Asians (n Z 1943)d 47.3 82.1
Non-East Asians (n Z 19,162) 58.5 94.8
TIA Z transient ischemic attack.
a China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singa
b China, South Korea, Taiwan, Hong Kong.
c China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singa
d China, Japan, South Korea, Taiwan.consistent across a wide range of patients. One should be
careful to integrate this information into patient care in
Asia. As mentioned in previous sections, Asians are prone
to bleeding due to warfarin use. Therefore, a more
detailed examination of the Asian subset in these RCTs is
important.
9.6.3. Asian sub-analyses of clinical trials
Although there were no large scaled RCTs to test the effi-
cacy of warfarin in Asians in the stroke prevention in AF,
several smaller or cohort studies suggested the superiority
of warfarin compared to aspirin or placebo in Asians.134
Among 71,783 participants in the four major RCTs of
NOACs,81e84 7650 patients were from Asia. The Asian sub-
analyses of all these RCTs have been published or pre-
sented.85e87,148 This information provides a great
opportunity for the understanding of both efficacy and
safety of the use of NOACs versus warfarin in Asia.
9.6.3.1. Background characteristics. The mean CHADS2
score and other risk factors for stroke in Asians and non-
Asians are shown in Table 11. In general, the mean
CHADS2 score were similar in Asians and non-Asians across
all four trials. The prevalence rate of previous stroke/TIA
was numerically higher in Asians than in non-Asians,
whilst hypertension and ages were higher in non-Asians.
9.6.3.2. Warfarin in Asians versus non-Asians. In these
four large-scale RCTs of NOACs, warfarin was tested
against NOACs for stroke prevention. There was a
substantial proportion of patients receiving warfarin
therapy, and a total of 7650 Asian patients were
included. It would be a great opportunity to analyze the
safety and efficacy of warfarin in Asians versus non-Asians.
Figure 5 shows the TTR (INR 2.0e3.0) and proportions of
patients with INR < 2.0 or INR > 3.0 in these RCTs.
Apparently, TTR was consistently lower in Asians than inAsians in four clinical trials.
Age  75 y
(%)
Diabetes
(%)
Stroke/TIA
(%)
Mean CHADS2
score
27.4 25.1 24.2 2.2
42.2 23.0 10.4 2.1
(mean age)
69.7 36.9 65.0 3.2
71.3 40.1 54.0 3.5
24.4 25.2 28.8 2.1
32.0 25.0 18.3 2.1
37.5 35.0 42.4 2.9
40.4 36.2 26.9 2.8
pore, Malaysia, Thailand, India.
pore, Malaysia.
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18
28.4 22.2
54.5
66.2
50.3
55.2 60
67
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10.1 14 12.6 15.7 11.4 15 8 12.8
0%
50%
100%
INR > 3.0
INR = 2.0-3.0
INR < 2.0
RE-LY ROCKET ARISTOTLE ENGAGE
Figure 5 International normalized ratios (INRs) in the ran-
domized trials. Asians in RE-LY included patients from China,
Japan, South Korea, Taiwan, Hong Kong, Philippines,
Singapore, Malaysia, Thailand, and India.85 Asians in ROCKET
included patients from China, South Korea, Taiwan, Hong Kong,
Philippines, Singapore, Malaysia, and Thailand.330 Asians in
ARISTOTLE included patients from China, Japan, South Korea,
Taiwan, Hong Kong, Philippines, Singapore, and Malaysia.87
East Asians in ENGAGE included patients from China, Japan,
South Korea, and Taiwan.88 Modified from Lip et al149 with
permission.
Figure 6 Bleeding events on warfarin in Asians versus non-Asians,
hemorrhage; (C) gastrointestinal bleeding; (D) all (major plus minor
912 C.-E. Chiang et al.non-Asians.95 Higher proportions of Asians had an INR of <
2.0, while non-Asians more commonly to have an INR >
3.0. These data suggest that Asians were less intensely
anticoagulated with warfarin in these RCTS. Other
factors associated with bleeding risk were generally
similar among Asians and non-Asians. For instance, the
mean HAS-BLED score was 2.9 in Asians and 2.8 in non-
Asians in the ROCKET AF trial, and it was 1.7 in Asians
and 1.8 in non-Asians in the ARISTOTLE trial.86,87
The safety endpoints, including major bleeding (pri-
mary safety endpoint), ICH, gastrointestinal bleeding, and
bleeding of any cause are shown in Figure 6.149 Even
though Asians were less intensely anticoagulated with
warfarin, the bleeding events, except gastrointestinal
bleeding, were generally higher in Asians than in non-
Asians. The event rates of ICH, the most devastating
bleeding event, were much higher in Asians than in non-
Asians. These data confirmed the finding from previous
report that Asians are prone to bleeding when treated
with warfarin.135
The efficacy endpoints, including stroke/SEEs (primary
efficacy endpoint), ischemic stroke, hemorrhagic stroke,
MI, and all-cause mortality are shown in Figure 7.149 Despite
similar CHADS2 score in Asians versus non-Asians in these
four RCTs, the event rates of stroke/SEEs, hemorrhagic
stroke, and ischemic stroke were higher in Asians, possibly
due to inadequate intensity of anticoagulation in Asiansfrom the randomized trials. (A) Major bleeding; (B) intracranial
) bleeding episodes. Modified from Lip et al149 with permission.
Figure 7 Major cardiovascular events on warfarin in Asians versus non-Asians, from the randomized trials. (A) Stroke and systemic embolization events; (B) ischemic stroke; (C)
hemorrhagic stroke; (D) myocardial infarction; (E) all-cause death. Modified from Lip et al149 with permission.
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914 C.-E. Chiang et al.(more patients with INR <2.0). The risk of MI and all-cause
mortality did not differ significantly.Fact
 When warfarin is used, Asian patients have a higher
risk of stroke, major bleeding, and ICH compared
with non-Asians, despite the average anti-
coagulation intensity of warfarin being lower in
Asians.9.6.3.3. NOACs in Asians versus non-Asians. The differ-
ences in efficacy endpoints (stroke/SEEs, ischemic stroke,
hemorrhagic stroke, MI, all-cause mortality, and CV
mortality) and safety endpoints (major bleeding, ICH,
gastrointestinal bleeding, and bleeding of any cause) in
the four RCTs have been analyzed and published.149 Table
12 summarizes the effectiveness and safety of each NOAC
comparing with warfarin. These important messages from
the Asian subanalyses of the four RCTs of NOACs strongly
suggested the great advantages of using NOACs in the
stroke prevention in AF patients in Asia. The performance
of most NOACs were even better in Asians than in non-
Asians. Although these are subgroup analyses,
randomization processes were undertaken in Asia, and
most of the confounders were randomized and evenly
distributed in the NOAC group and the warfarin
group.85e87,148 Moreover, the total number of Asian
patients is > 7600, more than any previous study on
anticoagulants in Asia. There has been no head-to-head
RCT to compare different NOACs. The superiority of one
NOAC over the other cannot be stated.
9.6.3.4. Meta-analysis of NOACs in Asia. In a recent meta-
analysis, the differences in efficacy and safety outcomes ofTable 12 Efficacy and safety endpoints of different NOACs in A
Stroke/
SEE
Ischemic
stroke
Hemorrhagic
stroke
Myocardial
infarction
All
dea
Dabigatran a
150 mg
V V V
Dabigatran a
110 mg
V
Rivaroxaban b
Apixaban c V
Edoxaban d
60 mg
V V
Edoxaban d
30 mg
V
GIZ gastrointestinal; NOACsZ non-vitamin K antagonist oral anticoa
V Z p value less than 0.05 when compared with warfarin.
a China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singa
b China, South Korea, Taiwan, Hong Kong.
c China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singa
d China, Japan, South Korea, Taiwan. Modified from Lip et al149 witNOACs in Asian patients were compared with non-Asian
patients.150 The five RCTs included RE-LY, ROCKET AF, J-
ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48,
comprising of 8928 Asian patients (5250 with NOACs and
3678 with VKAs) and 64,033 non-Asian patients (37,800
with NOACs and 26,233 with VKAs).81e88,148,151 There were
two separate analyses: meta-analysis for standard-dose
NOACs (dabigatran 150 mg, edoxaban 60 mg, rivaroxaban
20 mg, and apixaban 5 mg); and meta-analysis for low-
dose NOACs (dabigatran 110 mg, edoxaban 30 mg, and
rivaroxaban 15 mg).150
The efficacy of standard-dose NOACs and VKAs in Asians
and in non-Asians is shown in Figure 8.150 Standard-dose
NOACs significantly reduced stroke/SEE both in Asian and
non-Asian patients [odds ratio (OR), 0.65; 95% CI,
0.52e0.83; p < 0.001 for Asian patients; OR, 0.85; 95% CI,
0.77e0.93; p < 0.001 for non-Asian patients].150 The
reduction was more robust in Asian patients than in non-
Asian patients (p interaction Z 0.045). The effect of
standard-dose NOACs on ischemic stroke and MI was similar
to VKAs in both Asian and non-Asian patients (p
interaction Z 0.673 and 0.977, respectively). All-cause
mortality was significantly lower in both with standard-
dose NOACs than with VKAs (OR, 0.80; 95% CI, 0.65e0.98;
p Z 0.030 for Asian patients; OR, 0.91; 95% CI, 0.86e0.97;
p Z 0.003 for non-Asian patients; p
interaction Z 0.219).150
Figure 9 shows safety outcomes of standard-dose NOACs
in Asian versus non-Asian patients.150 Standard-dose NOACs
reduced major bleeding more in Asian than in non-Asian
patients (OR, 0.57; 95% CI, 0.44e0.74; p < 0.001 for Asian
patients; OR, 0.89; 95% CI, 0.76e1.04; p Z 0.143 for non-
Asian patients; p interaction Z 0.004). ICH was signifi-
cantly reduced in both populations with standard-dose
NOACs (OR, 0.33; 95% CI, 0.22e0.50; p < 0.001 for Asian
patients; OR, 0.52; 95% CI, 0.42e0.64; p < 0.001 for non-
Asian patients; p interaction Z 0.059). Standard-dose
NOACs had a more significant reduction in hemorrhagic
stroke in Asian than in non-Asian patients (OR, 0.32; 95% CI,sians.85e88,148
-cause
th
CV
death
Major
bleeding
Intracranial
hemorrhage
GI
bleeding
Bleeding of
any cause
NR V V V
NR V V V
V NR
NR V V NR V
V V V V
V V V
gulants; NRZ not reported; SEEZ systemic embolization events;
pore, Malaysia, Thailand, India.
pore, Malaysia.
h permission.
Figure 8 Efficacy outcomes of (A) stroke or systemic embolism, (B) ischemic stroke, (C) myocardial infarction, and (D) all-cause mortality for the standard-dose non-vitamin K
antagonist (VKA) oral anticoagulants (NOACs) versus VKAs. Modified from Wang et al150 with permission. CI Z confidence interval; OR Z odds ratio.
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Figure 9 Safety outcomes of (A) major bleeding, (B) intracranial hemorrhage, (C) hemorrhagic stroke, and (D) gastrointestinal bleeding for the standard-dose non-vitamin K
antagonist (VKA) oral anticoagulants (NOACs) versus VKAs. Modified from Wang et al150 with permission. CI Z confidence interval; OR Z odds ratio.
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Figure 10 Efficacy outcomes of (A) stroke or systemic embolism, (B) ischemic stroke, (C) myocardial infarction, and (D) all-cause mortality for the low-dose non-vitamin K
antagonist (VKA) oral anticoagulants (NOACs) versus VKAs. Modified from Wang et al150 with permission. CI Z confidence interval; OR Z odds ratio.
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Figure 11 Safety outcomes of (A) major bleeding, (B) intracranial hemorrhage, (C) hemorrhagic stroke, and (D) gastrointestinal bleeding for the low-dose non-vitamin K
antagonist (VKA) oral anticoagulants (NOACs) versus VKAs. Modified from Wang et al150 with permission. CI Z confidence interval; OR Z odds ratio.
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2016 AF Guidelines of THRS/TSOC 9190.19e0.52; p < 0.001 for Asian patients; OR, 0.56; 95% CI,
0.44e0.70; p < 0.001 for non-Asian patients; p
interaction Z 0.046) compared with VKAs. Moreover,
standard-dose NOACs increased the risk of gastrointestinal
bleeding in non-Asian patients but not in Asian patients
(OR, 1.44; 95% CI, 1.12e1.85; p Z 0.005 for non-Asian pa-
tients; OR, 0.79; 95% CI, 0.48e1.32; p Z 0.378 for Asian
patients; p interaction Z 0.041).
The comparison of low-dose NOACs and VKAs with regard
to the various efficacy outcomes is presented in
Figure 10.150 Low-dose NOACs had similar efficacy to VKAs
on stroke or SEE and ischemic stroke both in Asian and non-
Asian patients (p interaction Z 0.353 and 0.504, respec-
tively). With regard to MI, non-Asian patients had more
events with low-dose NOACs than with VKAs (OR, 1.28; 95%
CI, 1.06e1.55; p Z 0.010), whereas the effect of low-dose
NOACs seemed to be similar to VKAs in Asian patients (OR,
0.92; 95% CI, 0.48e1.79; pZ 0.816); however, there was no
statistical heterogeneity (p interactionZ 0.352). Low-dose
NOACs were associated with a significant reduction in all-
cause mortality in non-Asian patients and a trend for a
reduction in Asian patients (p interaction Z 0.934).
The safety outcomes of low-dose NOACs are presented in
Figure 11.150 Low-dose NOACs reduced major bleeding, ICH,
and hemorrhagic stroke in both Asian and non-Asian pa-
tients (p interaction Z 0.579, 0.661, and 0.944, respec-
tively). There was no difference in gastrointestinal bleeding
in Asians and non-Asians (p interaction Z 0.460).
Overall, standard-dose NOACs were more effective and
safer in Asians than in non-Asians. The increased risk of GI
bleeding was not found in Asians. Low-dose NOACs per-
formed similarly in efficacy in both populations, but the
safety was much better than warfarin in both populations.
Increased risk of MI was not found in Asians.150Recommendations
 Standard-dose NOACs are more effective and safer
than warfarin in Asians, and should be recommended
as first choice for the stroke prevention in Asians.
 Low-dose NOACs are equally effective as, but safer
than warfarin in Asians, and should be recommended
as therapeutic choice when standard-dose NOACs
are not appropriate, such as in patients with age 
75 years or in those patients with moderate to se-
vere chronic kidney disease [CKD; creatinine clear-
ance rate (CCr) 30e49 mL/min]. For apixaban, the
lower dose is used in patients with two or more of
the following criteria: age  80 years, body weight 
60 kg, or serum creatinine  1.5 mg/dL.
 Dabigatran is highly cost-effective in clinical settings
in Taiwan.9.6.4. Cost-effectiveness of NOAC in Taiwan
Several cost-effectiveness analyses comparing warfarin
with dabigatran have been done in the west and have
shown an incremental cost-effectiveness ratio between
CAD$9,041 and USD$86,000 per quality-adjusted-life-year
(QALY).152,153 However, results from these studies may not
be applicable to Asian countries, where the disease pat-
terns and treatment patterns are different. The low rate ofantithrombotic therapy and the low INR maintained with
warfarin users in Taiwan suggest that the avoidable
morbidity and mortality due to under-utilization could be
significant if a more effective and safer medication can be
adopted for warfarin-eligible patients.118 Moreover, the
healthcare systems and healthcare cost structures in
Taiwan are very different from those in western countries
and other Asian countries.
A cost-effectiveness analysis to evaluate the value of
dabigatran to prevent stroke and SEE in patients with AF in
Taiwan has recently been reported.117 Dabigatran was
given through sequential dosing, where patients aged <
80 years received 150 mg of dabigatran twice a day and the
dosage was reduced to 110 mg for patients aged  80 years.
Dabigatran was compared with warfarin under two sce-
narios: the real-world adjusted-dose warfarin assuming all
AF patients eligible for warfarin were given the medication
and maintained at the INR observed in routine clinical
practice in Taiwan, and the real-world prescribing behavior
similar to the treatment with antithrombotics in real-world
practice in Taiwan, where eligible patients could receive
warfarin, aspirin, or no treatment. It was found that the
incremental cost-effectiveness ratio was US$280/QALY in
the real-world prescribing scenario and US$10,551/QALY in
real-word warfarin use.117 It is suggested that dabigatran is
highly cost-effective in a clinical practice setting where
warfarin has been significantly undeused.117 Cost-
effectiveness analysis of other NOACs has not been re-
ported in Taiwan.9.6.5. Reversal agents
Patients who experienced major bleeding on dabigatran
required a shorter stay in intensive care and had a trend to
lower mortality compared with those who had major
bleeding on warfarin.154 Nonetheless, it has always been a
concern that NOACs do not have reversal agents to
normalize the coagulation activity. Idarucizumab, a mono-
clonal antibody fragment, binds dabigatran with an affinity
that is 350 times as high as that observed with thrombin.155
Consequently, idarucizumab binds free and thrombin-
bound dabigatran and neutralizes its activity.155 The RE-
VERSE AD study was undertaken to examine the efficacy
and safety of idarucizumab in dabigatran-treated patients
who had serious bleeding or required urgent procedures.156
In the recent interim analysis of the first 90 patients,
idarucizumab completely reversed the anticoagulant effect
of dabigatran within minutes.156 Immediately after the
administration of idarucizumab, the concentration of un-
bound dabigatran was reduced to a level at or near the
lower limit of quantification in all but one patient.156 On
October 16, 2015, the US FDA granted accelerated approval
to idarucizumab (Praxbind) to reverse the blood-thinning
effects of dabigatran rapidly.
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920 C.-E. Chiang et al.Andexanet-a (andexanet) is a specific reversal agent
that is designed to neutralize the anticoagulant effects of
both direct and indirect factor Xa inhibitors.157 Andexanet
is a recombinant modified human factor Xa decoy protein
that is catalytically inactive but that retains the ability to
bind factor Xa inhibitors in the active site with high affinity
and a 1:1 stoichiometric ratio. In a recently published
clinical trial, healthy older volunteers were given 5 mg of
apixaban twice daily or 20 mg of rivaroxaban daily.158
Among the apixaban-treated participants, anti-factor Xa
activity was reduced by 94% among those who received an
andexanet bolus, as compared with 21% among those who
received placebo (p < 0.001), and unbound apixaban con-
centration was reduced by 9.3 ng/mL versus 1.9 ng/mL
(p < 0.001); thrombin generation was fully restored in 100%
versus 11% of the participants (p < 0.001) within
2e5 minutes. Among the rivaroxaban-treated participants,
anti-factor Xa activity was reduced by 92% among those
who received an andexanet bolus, as compared with 18%
among those who received placebo (p < 0.001), and un-
bound rivaroxaban concentration was reduced by 23.4 ng/
mL versus 4.2 ng/mL (p < 0.001); thrombin generation was
fully restored in 96% versus 7% of the participants
(p < 0.001). These effects were sustained when andexanet
was administered as a bolus plus an infusion. It is concluded
that andexanet reversed the anticoagulant activity of
apixaban and rivaroxaban in older healthy participants
within minutes after administration and for the duration of
infusion, without evidence of clinical toxic effects.158 The
ongoing ANNEXA-4 phase 3be4 study (ClinicalTrials.gov
number, NCT02329327) is evaluating the efficacy and
safety of andexanet in patients with factor Xa inhib-
itoreassociated acute major bleeding.0
Annual ICH%
Annual stroke
CHA2DS2-VASc=1
Figure 12 Rationale for using CHA2DS2-VASc score Z 1 for
threshold of using non-vitamin K antagonist oral anticoagulants
in Asians. ICH Z intracranial hemorrhage.
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Figure 13 Management algorithm for stroke prevention in
Asians. AF Z atrial fibrillation; NOAC Z non-vitamin K antag-
onist oral anticoagulant. (Modified from Lip et al.149 with
permission.)9.7. Management algorithm in Asians
In recently updated AF guidelines,91,93,159 warfarin was still
placed as one of the first choices for stroke prevention. In
the recent analysis of the Asian data from the four
RCTs,96,150 it is clear that warfarin is difficult to use in
Asians, and well-controlled INRs do not preclude the risk of
ICH.160 NOACs are much better than warfarin both in effi-
cacy and the safety endpoints, and thus NOACs should be
preferentially indicated for stroke prevention in AF for
Asians.150 Aspirin is ineffective for stroke prevention in
Asian AF patients,112 and antiplatelet therapy should not be
used unless both NOACs and warfarin are refused or not
tolerated.
Because the CHA2DS2-VASc score has outperformed other
scoring systems in predicting AF-associated stroke in
Asians,161,162 the TSOC/THRS AF guidelines strongly
recommend the use of CHA2DS2-VASc score in the prediction
of stroke risk in Taiwan.
There is some debate as to whether we should treat
patients with a CHA2DS2-VASc score  1 or  2, but the net
clinical benefit is positive in favor of OAC in patients with at
least one stroke risk factor, but neutral or negative for
aspirin.163
In a recent report using the NHIRD in Taiwan,161 a total
of 186,570 AF patients without antithrombotic therapy
were analyzed. The annual risk of ischemic stroke inpatients with a single additional stroke risk factor [i.e.,
CHA2DS2-VASc scoreZ 1 (men) or 2 (women)] was 2.75% for
men and 2.55% for women.162 These numbers are well
above the annual risk of NOAC-induced ICH in Asians, but
were not much different from the risk of warfarin-induced
ICH in Asians (Figure 12). It would be reasonable to suggest
starting the use of NOACs instead of warfarin in Asians with
a CHA2DS2-VASc score Z 1 in men or 2 in women. Since AF
patients with a CHA2DS2-VASc score Z 1 were included in
the RE-LY trial and the ARISTOTLE trial but not included in
the ROCKET or ENGAGE trials, rivaroxaban and edoxaban
are recommended only in patients with a CHA2DS2-VASc
score  2.
The CHA2DS2-VASc score has been shown to be best to
identify low risk patients, even in Asian cohorts.164 Hence,
rather than a categorized approach to stroke risk stratifi-
cation, the initial management approach should be to
initially identify low risk patients (i.e. CHA2DS2-VASc score
2016 AF Guidelines of THRS/TSOC 9210 in men, 1 in women), no antithrombotic agent is recom-
mended. The next step is to offer stroke prevention (which
is OAC) to patients with  1 stroke risk factors. The sug-
gested management algorithm in AF patients in Asia is
illustrated in Figure 13.Recommendations
 NOACs should be preferentially indicated in stroke
prevention for AF in Asia.
 The first step is to identify those patients with low
risk (i.e. CHA2DS2-VASc score 0 in men, 1 in women),
no antithrombotic agent is recommended.
 For patients with only one stroke risk factor using
CHA2DS2-VASc (i.e. scoreZ 1 in men or 2 in women),
dabigatran or apixaban are recommended.
 For CHA2DS2-VASc score  2 (or  3 in women), any
NOAC, including dabigatran, apixaban, rivaroxaban,
or edoxaban, is recommended.9.8. NOACs in clinical practice
9.8.1. Switching of OAC
An algorithm for switching anticoagulants is shown in
Figure 14. INR monitoring is needed when switching be-
tween NOACs and warfarin. A bridging method (rivarox-
aban, apixaban, and edoxaban) or overlapping method
(dabigatran and edoxaban) can be used. INR should be
checked at least twice weekly. The switching between
NOAC and parenteral agents [unfractionated heparin
(UFH) or low molecular weight heparin (LMWH)] is much
easier.NO
Warf
LMWH
DC NOAC
Start LMWH at the next dose
DC LMWH
Start NOAC at the Ɵme of
next dose of LMWH
Stop warfarin,
Add NOAC when INR < 2
A: Apixaban
D: Dabigatran
E: Edoxaban
R: Rivaroxaban
W: Warfarin
Figure 14 Switching algorithm of anticoagulants. DC Z discont
1.73 m2); INR Z international normalized ratio; LMWH Z low mol
anticoagulant; UFH Z unfractionated heparin.9.8.2. Measurement of anticoagulation activity
It is not recommended to monitor the coagulation activity
routinely. Neither the dose nor the dosing intervals should
be altered in response to changes in laboratory coagulation
parameters for the current registered indications.141 In
certain emergent conditions, such as serious bleeding and
thrombotic events, requirement for urgent surgery, and
suspected overdosing, assessment of drug exposure and a
qualitative assessment of anticoagulation effect may be
needed. Also, this may be needed in NOAC-users suffering
from ischemic stroke when thrombolytic therapy is to be
considered, to ascertain if there is a systemic anticoagulant
effect from the NOAC.
The coagulation activity of NOACs should be checked at
the trough level, i.e., 12 hours or 24 hours after ingestion of
the same dose. The activated partial thromboplastin time
(aPTT) may provide a qualitative assessment of the pres-
ence of dabigatran.141,165 If the aPTT level at trough (i.e.
12e24 hours after ingestion) still exceeds two times the
upper limit of normal, this may be associated with a higher
risk of bleeding. By contrast, a normal aPTT in dabigatran-
treated patients can be used to exclude any relevant
remaining anticoagulant activity. The ecarin clotting time
assay can provide a direct measurement of the activity of
dabigatran, while dilute thrombin time can more accu-
rately predict dabigatran anticoagulation. Both of these
tests are not routinely performed. Dabigatran has little
effect on the prothrombin time (PT) and INR at clinically
relevant plasma concentrations.141
Rivaroxaban has a concentration-dependent prolonga-
tion of PT, but the prolongation has no known relation with
bleeding risk. For apixaban and edoxaban, the PT cannot be
used for assessing their anticoagulant effects, and an anti-
factor Xa activity assay should be used. One should be
careful that conversion of PT to INR is not corrected for the
variations and even increases the variability. Therefore,AC
arin
UFH
Bridging (R, A, E)
Parenteral + warfarin
Ɵll INR ≥ 2
Overlapping (D)
eGFR ≥ 50: D+W for 3d
eGFR30-49: D+W for 2d
Overlapping (E)
50% E+W, Ɵll INR ≥ 2
DC NOAC
Start UFH at the next dose
DC UFH
Start NOAC immediately
(E: aŌer 4 h)
inue; eGFR Z estimated glomerular filtration rate (mL/min/
ecular weight heparin; NOAC Z non-vitamin K antagonist oral
922 C.-E. Chiang et al.the INR is completely unreliable for the evaluation of Xa
inhibitory activity.141
There have been no data on the true cut-off levels of any
coagulation test to predict the bleeding risk of NOACs.
Moreover, whether measurement of drug levels and dose
adjustment based on laboratory parameters can reduce
bleeding risk has not been studied.141Recommendations
 Routine measurement of coagulation activity for
NOACs is not recommended.
 In rare conditions, such as in NOAC-users suffering
from ischemic stroke when thrombolytic therapy is
considered, monitoring coagulation activity may be
useful.
 aPTT can be used to assess the presence of an
anticoagulant effect from dabigatran.
 PT, but not INR, can be used to assess the presence
of an anticoagulant effect from rivaroxaban.
 Anti-factor Xa assay can be used to assess the
anticoagulant effect of the factor Xa inhibitors
(rivaroxaban, apixaban, edoxaban).
Recommendations
 For patients with stage III CKD (CCr 30e49 mL/min),
dabigatran 110 mg twice daily, rivaroxaban 15 mg
once daily, apixaban 2.5 mg twice daily, or edoxaban
30 mg once daily may be considered.
 For patients stage IV or V CKD, including those on
hemodialysis, NOACs should not be used. Warfarin
with high TTR (> 70%) is recommended.9.8.3. Drugedrug interaction
Unlike warfarin, NOACs are mostly free from foodedrug
interaction. Drugedrug interactions, however, need further
address. An important interaction mechanism for all NOACs
consists of significant re-secretion via a P-gp transporter
after absorption in the gut. An inhibition or induction of P-
gp results in significant changes in plasma levels. CYP3A4-
type cytochrome P450-dependent elimination plays a more
minor role in the interaction. Some important drugedrug
interactions for NOACs are shown in Table 13.
9.8.4. Patients with chronic kidney disease
All NOACs are partially eliminated by the kidney (Table 8).
Patients with mild-to-moderate CKD (CCr, 30e89 mL/min)
have been randomized in RCTs of four NOACs, and the ef-
ficacy and safety have been confirmed.81e84 For patientsTable 13 Drugedrug interaction for NOACs.
Mechanism
Amiodarone P-gp
Dronedarone P-gp, CYP3A4
Verapamil P-gp
Rifampin P-gp, CYP3A4
HIV protease inhibitor P-gp, CYP3A4
Intraconazole and ketoconazole P-gp, CYP3A4
Carbamazepine, phenobarbital, and phenytoin P-gp, CYP3A4
HIV Z human immunodeficiency virus; NOACs; non-vitamin
X Z contraindication.who have a CCr of 30e49 mL/min dabigatran 110 mg,
instead of 150 mg, is recommended by some guide-
lines,78,141 although subgroup analysis still favors 150 mg in
patients with a CCr of 30e49 mL/min.166
There are no efficacy and safety data for NOACs in pa-
tients with advanced CKD (CCr < 30 mL/min), and these
guidelines recommend against their use in such patients,
similar to ESC guidelines.78,141 For patients with end-stage
CKD, neither warfarin nor NOACs have prospective data.
Warfarin with high TTR (> 70%) is recommended in patients
with end-stage CKD by most guidelines.141
Renal function needs to be monitored yearly in patients
on NOACs to detect changes in renal function and dose
adjust accordingly. For patients with impaired renal func-
tion (CCr < 60 mL/min), renal function should be checked
every 6 months, especially in patients receiving dabigatran
or edoxaban which depend more on renal clearance.141 The
EHRA practical guide suggests that if renal function is
impaired (i.e. CCr  60 mL/min, one could specify a
recheck interval of a number of months.1429.8.5. Patients with coronary heart disease
Both during elective or urgent percutaneous coronary
intervention (PCI), NOACs should be preferably be tempo-
rarily discontinued in patients with stable CHD or upon
presentation of ACS, as what has been followed during all
the four RCTs of NOACs.141 Temporary discontinuation of
NOACs allows safe initiation of antiplatelet therapy and
standard anticoagulation practices periprocedurally.141 The
use of ticagrelor or prasugrel as part of the triple therapyDabigatran Rivaroxaban Apixaban Edoxaban
50% dose
If  75 y
50% dose
If  75 y
50% dose
If  75 y
50% dose
If  75 y
X No data No data 50% dose
50% dose No data No effect No data
X X X X
X X X X
X X X 50% dose
X X X X
K antagonist oral anticoagulants; P-gp Z P-glycoprotein;
2016 AF Guidelines of THRS/TSOC 923regimen is not recommended, given that their bleeding risk
associated with NOACs is unknown.167 For all stable CHD
patients with AF, the rule-of-thumb is to use anti-
coagulation as monotherapy and to discontinue any anti-
platelet agents at 1 year after presentation with their ACS,
except for those with a very high risk of coronary events
and an acceptably low bleeding risk.141Recommendations
 During both elective or urgent PCI, NOACs should be
preferably discontinued in patients with stable CHD
or upon presentation of ACS, to allow safe initiation
of antiplatelet therapy and standard anticoagulation
practices periprocedurally.
 The inclusion of ticagrelor or prasugrel in the triple
therapy is not recommended, because their bleeding
risk associated with NOACs is unknown.
 Following presentation with an ACS or a PCI/stent
procedure, AF patients should be managed with
triple therapy (OAC plus aspirin plus clopidogrel), for
3e6 months (shorter duration if high bleeding risk)
followed by dual therapy (OAC plus single anti-
platelet, preferably clopidogrel) until 1 year,
following which the patient should be managed with
OAC monotherapy alone. OAC refers to warfarin with
TTR > 70% or a NOAC.
 Where an NOAC is used in combination with anti-
platelet therapy, the lower tested NOAC dose used
for stroke prevention in AF should be used (i.e.
dabigatran 110 mg twice daily, rivaroxaban 15 mg
once daily, apixaban 2.5 mg twice daily, edoxaban
30 mg).
Recommendations
 Strategies that reduce the bleeding risk in patients
with AF and ACS include: (1) low doses of aspirin
(75e100 mg), especially when combined with a
P2Y12 inhibitor; (2) third-generation DESs to mini-
mize the duration of triple therapy; (3) a radical
approach for interventional procedures to reduce
the risk of access site bleeding; and (4) proton-pump
inhibitors should be considered in all patients with a
combination of antiplatelets and anticoagulants.
 In patients with an ACS and treated with medical
therapy or PCI, 3e6 months of triple therapy should
be recommended prior to stepping down to double
therapy.
 The duration of triple therapy can be shortened to
1 month or the triple therapy can be replaced with
dual therapy (i.e. OAC plus clopidogrel) in patients
at extremely high risk of bleeding.
 Standard triple therapy for 12 months can be
considered in patients receiving a first-generation
DES or those with a combination of very high athe-
rothrombotic risk and low bleeding risk.9.8.5.1. Patients with acute coronary syndrome. There
has been no RCT comparing VKA and NOACs in patients
with AF undergoing PCI for ACSs. Moreover, there are no
RCTs to evaluate new antiplatelets, such as prasugrel or
ticagrelor, in patients with AF receiving either VKA or
NOACs. In general, adding a single antiplatelet therapy
drug to any type of oral anticoagulants increases the risk
of major bleeding by 60e80%; adding DAPT increases the
risk of major bleeding by 130% over anticoagulants
alone.168,169 Therefore, these data indicate that triple
therapy should be kept as short as possible. Strategies
that reduce the bleeding risk in patients with AF and ACS
include: (1) low doses of aspirin (75e100 mg), especially
when combined with a P2Y12 inhibitor; (2) new-
generation drug-eluting stents (DES) to minimize the
duration of triple therapy; (3) a radical approach for
interventional procedures to reduce the risk of access
site bleeding; and (4) proton-pump inhibitors should be
considered in all patients with a combination of
antiplatelets and anticoagulants.141
In stabilized patients who do not have recurrent
ischemia or need for other invasive procedure, OAC can be
restarted after parenteral anticoagulation is stopped. The
same NOAC that the patient was taking prior to the ACS can
be restarted.141In patients with an ACS and treated with medical ther-
apy or PCI, 6 months of triple therapy should be recom-
mended prior to stepping down to double therapy. The
duration of triple therapy can be shortened to 1 month or
the triple therapy can be replaced with double therapy in
patients with an extremely high risk of bleeding. Standard
12-month triple therapy can be considered in patients
receiving a first-generation DES or those with a combination
of very high atherothrombotic risk and low bleeding risk.1419.8.5.2. Patients with elective PCI. In stabilized patients
who do not have recurrent ischemia or need for other
invasive procedure, OAC can be restarted after parenteral
anticoagulation is stopped. The same NOAC that the patient
was taking prior to the ACS can be re-started.141
All phase III trials of NOACs allowed the concomitant use
of aspirin ( 100 mg/d) for patients undergoing PCI, but
only the RE-LY trial included a substantial number of pa-
tients on concomitant clopidogrel with or without
aspirin.170 Several RCTs were ongoing to test NOACs versus
warfarin in combination with aspirin and/or P2Y12 in-
hibitors (RE-DUAL-PCI for dabigatran NCT 02164864,
PIONEER-AF-PCI for rivaroxaban NCT 01830543, and
AUGUSTUS for apixaban NCT 02415400).
AF patients should be managed with triple therapy (OAC
plus aspirin plus clopidogrel), for 3e6 months (shorter
duration if high bleeding risk) followed by dual therapy
(OAC plus single antiplatelet, preferably clopidogrel) until
1 year, following which the patient should be managed with
OAC monotherapy alone. OAC refers to warfarin with TTR >
70% or a NOAC.141 In patients with a high bleeding risk or a
low atherothrombotic risk, the duration of triple therapy
can be shortened and the duration of combination therapy
can be abbreviated to 3e6 months. By contrast, longer
duration of triple therapy (3e6 months) may be considered
924 C.-E. Chiang et al.in patients receiving first-generation DES, or in patients
with high atherothrombotic risk and low bleeding risk.Recommendations
 For patients receiving elective PCI, triple therapy
[OAC plus low dose aspirin (75e100 mg) plus clopi-
dogrel] 1 month (for a bare metal stent or newer
DES) is recommended, thereafter stepping down to
double therapy (OAC and clopidogrel) until 1 year.
OAC alone is adequate after 1 year.
 In patients with a high bleeding risk or a low athe-
rothrombotic risk, the duration of triple therapy (for
a bare metal stent or newer DES) can be shortened
and the duration of dual therapy (with OAC and
clopidogrel) can be abbreviated to 3e6 months. OAC
alone is adequate thereafter.
 Longer duration triple therapy (3e6 months) may be
considered in patients receiving first-generation
DES, or in patients with high atherothrombotic risk
and low bleeding risk, thereafter stepping down to
double therapy (with OAC and clopidogrel) until
1 year. OAC alone is adequate after 1 year.
 When VKA is combined with DAPT, the preferred INR
is 2.0e2.5.
 When an NOAC is combined with DAPT, lower doses
of NOACs are preferred, such as dabigatran 110 mg
twice daily, rivaroxaban 15 mg once daily, apixaban
2.5 mg twice daily, or edoxaban 30 mg once daily.
 There is no preference for one NOAC over another.
Recommendations
 NOACs as a group are superior to warfarin for sec-
ondary prevention stroke prevention.
 The combination of aspirin plus OAC does not pre-
vent ischemic stroke better than OAC alone, and
should be restricted to specific high-risk periods.
Recommendations9.8.5.3. Patients with chronic stable coronary heart disease.
Combining single antiplatelet therapy or DAPT with chronic
NOAC or VKA significantly increases bleeding risk.170e172
There is no RCT comparing VKA and NOAC in this setting.
Patients with stable CHD who have AF should receive
anticoagulation, depending on their CHA2DS2-VASc score.
Anticoagulation alone without additional antiplatelet is
recommended for most AF patients who have stable
CHD.141,167,173 A recent Danish registry showed that adding
an antiplatelet agent to VKA in stable CHD patients
increased bleeding risk without any benefits in
atherothrombotic or thromboembolic events.172 In Asian
patients, NOACs are preferred over warfarin for patients
with AF and stable CHD.149Recommendations
 Monotherapy with an NOAC is preferable for patients
with AF and stable CHD. This suggestion is applicable
to all NOACs.
 In the absence of direct comparative studies, no
particular NOAC can be favored over another.
 The first step when encountering OAC-related ICH is
discontinuation of the drug and supportive therapy.
 PCC, aPCC, and activated factor VII can be used to
correct coagulation status.
 Idarucizumab can be used as a reversal agent in
patients receiving dabigatran.9.8.6. Patients with stroke
Warfarin is superior to aspirin and placebo in the prevention
of recurrent stroke after TIA or stroke in patients withAF.174,175 All RCTs comparing NOACs versus warfarin had
subgroups of patients with prior stroke or TIA. In a meta-
analysis of 14,527 patients with prior stroke or TIA from
the RE-LY trial, the ROCKET AF trial, and the ARISTOTLE
trial, NOACs were associated with a significant reduction in
the incidence of recurrent stroke and SEEs compared with
warfarin (OR 0.85, CI 0.74e0.99).176 The risk of major
bleeding was also decreased (OR 0.86, CI 0.75e0.99),
mainly due to a significant reduction in the incidence of
hemorrhagic stroke (OR 0.44, CI 0.32e0.62).
Use of combination therapy with an OAC and an anti-
platelet after TIA or stroke is not suggested, because
combination therapy did not prevent ischemic events, but
increased the risk of major bleeding.174,175,177 In patients
suffering from stroke or TIA during well-treated warfarin
therapy, substitution with a NOAC is reasonable.174,1759.8.6.1. Patients with acute hemorrhagic stroke. Hemor-
rhagic stroke is a complication of anticoagulant therapy.
VKA accounts for 12e14% of patients with ICH,178 a risk that
is even greater in Asian patients.95 In the RE-LY trial,
patients with ICH on dabigatran had the same poor
prognosis as patients on warfarin.179 The first step when
encountering OAC-related ICH is discontinuation of the
drug and supportive therapy. The coagulation status of
patients under NOAC should be corrected as soon as
possible, by using prothrombin complex concentrate
(PCC), activated PCC (aPCC), and activated factor VII. In
patients on dabigatran, the specific reversal agent,
idarucizumab (a humanized antibody fragment that
specifically binds dabigatran), can be used. Its effect has
been supported by a recent clinical study.1569.8.6.2. Patients with acute ischemic stroke. In patients
on NOACs presenting with acute ischemic stroke, throm-
bolytic therapy should not be undertaken within 48 hours
after the last administration of NOAC.141 In case of
uncertainty concerning last NOAC dosage time, a
2016 AF Guidelines of THRS/TSOC 925prolonged aPTT (for dabigatran) or prolonged PT (for
rivaroxaban) indicates that the patient is anticoagulated
and thrombolysis should not be given. In patients treated
with warfarin, the risk of ICH with use of thrombolytic
agents appears to be low when the INR is  1.7.180 We do
not recommend the use of thrombolytics in situations
with uncertainty about the anticoagulation status. In this
situation, mechanical recanalization of occluded vessels
with stent retrievers may be considered as an alternative
treatment option.141
Decision on timing to start NOACs after acute ischemic
stroke depends on infarct size and stroke severity.141 Rec-
ommendations on the initiation of anticoagulation are
based on consensus opinion,141 in what is known as the 1-3-
6-12 day rule: in patients with TIA, NOAC can be initiated at
Day 1. In patients with mild stroke [National Institute of
Health Stroke Scale (NIHSS) < 8], NOAC can be initiated
after 3 days, or after ICH is excluded by imaging modality
[computed tomography (CT) or magnetic resonance imaging
(MRI)]. In patients with moderate stroke (NIHSS 8e16),
NOAC can be initiated after 5e7 days, and in severe stroke
(NIHSS > 16) after 12e14 days.141Recommendations
 In patients on NOACs presenting with acute ischemic
stroke, thrombolytic therapy should not be under-
taken within 48 hours after the last administration of
NOAC, unless coagulation tests specific for the in-
dividual NOAC reveal low or absent anticoagulant
effect.
 In patients on warfarin presenting with acute
ischemic stroke, thrombolytic therapy can be given
if INR is  1.7.
 Mechanical recanalization of occluded vessels with
stent retrievers may be considered as an alternative
treatment option for patients with acute ischemic
stroke with proximal intracranial artery occlusion
who are effectively anticoagulated with a NOAC.
 Reinitiation of anticoagulation can be based on the
1-3-6-12 day rule: in patients with TIA, NOAC can be
initiated at Day 1. In patients with mild stroke
(NIHSS < 8), NOAC can be initiated after 3 days, or
after ICH is excluded by imaging modality (CT or
MRI). In patients with moderate stroke (NIHSS 8e16),
NOAC can be initiated after 5e7 days, and in severe
stroke (NIHSS > 16) after 12e14 days.
Recommendations
 The use of NOAC in patients with a history of ICH
should be individualized.
 NOAC can be restarted after 4e8 weeks if car-
dioembolic risk is high and the risk of new ICH is low.
 For patients with low cardioembolic risk and high
ICH risk, the following risk factors for increasing risk
of ICH should be evaluated prior to decision of using
NOACs: lobar bleeds, cortical bleeds, amyloid angi-
opathy, severe white matter lesions, multiple
microbleeds on MRI, chronic alcoholism, and need
for DAPT after PCI.
 In patients with epidural and traumatic subdural
hematoma, NOAC can be given after 4 weeks.
 For nontraumatic subdural (unless due to uncon-
trolled INR in patients with VKA), NOAC is
contraindicated.9.8.6.3. Patients with a history of hemorrhagic stroke. It
is always a difficult decision on whether to initiate OAC in
patients with a history of ICH. A recent Danish cohort study
showed that in patients with a history of ICH OAC treatment
was associated with a significant reduction in ischemic
stroke/all-cause mortality rates (0.55, CI 0.39e0.78) in
patients on oral anticoagulant treatment in comparison
with no treatment.181 Survival benefit was also reported
from a recent cohort study from Germany.182 OAC
resumption showed fewer ischemic complications [OAC:9/172 (5.2%) vs. no OAC: 82/547 (15.0%); p < 0.001] and
not significantly different hemorrhagic complications
[OAC: 14/172 (8.1%) vs. no OAC: 36/547 (6.6%);
p Z 0.48]. Propensity-matched survival analysis in
patients with AF who restarted OAC showed a decreased
HR of 0.258 (95%CI, 0.125e0.534; p < 0.001) for long-
term mortality.182 In a recent report from Taiwan NHIRD,
warfarin use may be beneficial for AF patients with prior
ICH having a CHA2DS2-VASc score  6.183 Whether the use
of NOACs can lower the threshold for treatment deserves
further study.183
For patients with low cardioembolic risk and high ICH
risk, the indication for OAC should be re-evaluated. Risk
factors for increasing the risk of recurrence of ICH include:
older age, persistent uncontrolled hypertension, lobal
bleeds, cortical bleeds, amyloid angiopathy, severe white
matter lesions, multiple microbleeds on MRI, chronic alco-
holism, and need for DAPT after PCI.141 On the other hand,
NOAC can be restarted after 4e8 weeks if cardioembolic
risk is high and the risk of new ICH is low. To decrease the
risk of second episode ICH, unnecessary antiplatelet should
be discontinued,170 and the blood pressure (BP) should be
controlled to < 130/80 mmHg.184
One should know that in all the RCTs of NOACs, a history
of spontaneous ICH was an exclusion criteria, unless the
causes of the bleeding have been reversed. These revers-
ible causes include uncontrolled hypertension, triple ther-
apy, and INR > 4e5 in patients on VKAs.141 The subtypes of
ICH are also related to the strategy of anticoagulation. In
patients with epidural (always traumatic) and traumatic
subdural hematoma, NOAC can be given after 4 weeks. For
nontraumatic subdural hematoma (unless due to uncon-
trolled INR in patients with VKA), NOAC is contra-
indicated.141 Otherwise NOAC can be used after 4 weeks.9.8.7. Perioperative use
For AF patients with higher thromboembolic risk treated
with VKAs, bridging with LMWH or heparin was a generally
accepted strategy. However, in a large systemic review and
Table 14 Elective surgical interventions with low and
high bleeding risk.
Not clinically important bleeding risk
Superficial surgery (abscess incision, small excisions, etc.)
Dental procedures
Ophthalmic procedures (cataract or glaucoma)
Endoscopy without biopsy
Minor bleeding risk
Endoscopy with biopsy
Prostate or bladder biopsy
Electrophysiological study or catheter ablation
for right-sided SVT
Coronary angiography
Pacemaker/CRT device/ICD implantations
Hemorrhoidal surgery
Cholecystectomy
Abdominal hernia repair
Arthroscopy
Major bleeding risk
Catheter ablation of left-sided SVT
Liver biopsy
Kidney biopsy
Transurethral prostate resection
Spinal or epidural anesthesia, lumbar puncture
Neurosurgery
Cardiovascular and thoracic surgery
Abdominal surgery
Major orthopedic surgery
Extracorporeal shockwave lithotripsy
Adapted from Spyropoulos et al188 and Heidbuchel et al.141,189.
CRT Z cardiac resynchronization therapy; ICD Z implantable
cardioverter defibrillator; SCT Z supraventricular tachycardia.
926 C.-E. Chiang et al.meta-analysis of 34 observational studies of bridging anti-
coagulation,185 Siegal et al185 found an odds ratio of 3.6 (CI
1.52e8.50) for major bleeding with bridging vs. non-
bridging, and no significant difference in thromboembolism
or mortality. Therefore, the role of bridging strategy has
been questioned.186 The recent published BRIDGE trial
provided the most compelling evidence that routine
bridging in moderate-risk patients is harmful.187 In the
BRIDGE trialda randomized, double-blinded, placebo
controlled noninferiority studyd1884 AF patients (valvular
and nonvalvular) who were undergoing a procedure with
planned warfarin interruption were randomized to anti-
coagulation bridging with the low molecular-weight hepa-
rin, dalteparin, or placebo. The average CHADS2 score was
2.3, making the study population largely moderate risk for
TE. The primary endpoints were arterial TE and major
bleeding. The rate of arterial TE in the placebo group was
noninferior to the bridging group (0.4% vs. 0.3%; p Z 0.01
for noninferiority). Major and minor bleeding in the placebo
group was significantly less than that in the bridging group
(1.3% vs. 3.2%; p Z 0.005; 12% vs. 20.9%; p Z 0.001;
respectively). There was no measurable difference among
MI, deep vein thrombosis, pulmonary embolism, or death.
This study confirms that no bridging is noninferior to
bridging for preventing TE and is superior for reducing
bleeding events.187
Unlike warfarin, NOACs are all rapidly absorbed after
oral intake and reach maximal plasma concentration within
2e4 hours. After discontinuation, their anticoagulant ef-
fects diminish quickly because of short half-lives. These
features of NOACs facilitate rapid interruption and rein-
troduction around the time of surgery. Therefore, bridging
therapy with intravenous infusion of heparin or subcu-
taneous injection of LMWH is generally not necessary in
NOAC-treated patients. The decision about the strategy of
NOACs during the perioperative period should be made
balancing the risk of bleeding against the risk of thrombo-
embolism. Importantly, physicians and surgeons should try
their best in technical aspects to reduce the bleeding
complications of interventions, which may require pro-
longed interruption of NOACs and therefore expose patients
to a higher risk of thromboembolic events.
For interventions that cause nonclinically important
bleeding risk and/or when complete local hemostasis can
be achieved easily, it may not be necessary to stop NOACs
during the perioperative period (Table 14).141,188,189 These
interventions include dental procedures (such as tooth
extraction and abscess incision), cataract or glaucoma
surgery and endoscopy examination without tissue biopsy.
Practically, these procedures can be scheduled at the
trough concentration of the NOACs (12 hours after the last
intake of dabigatran/apixaban; 24 hours after the last
dosage of rivaroxaban and edoxaban). NOACs could be
prescribed 4e6 hours postprocedures if complete hemo-
stasis is achieved. In this way, patients just delay the
scheduled dosage of NOACs for several hours without miss
any dosage. However, patients should be informed about
the potential risk of bleeding, and they should contact the
physicians if the bleeding does not stop or recur.
Although there are no universal definitions to classify
procedures as minor (low) or major (high) bleeding risk,the classifications for some procedures are proposed based
on the recommendations of some available literature
(Table 14).141,188,189 Generally, a reasonable estimate of
perioperative major bleeding with the use of periproce-
dural anticoagulants is 2e4% for major surgery (major
bleeding risk) and 0e2% for nonmajor surgery or minor
procedures (minor bleeding risk).188 The time from the
interruption of NOACs to the surgical procedures depends
on the risk of bleeding and the renal function (Tables 14
and 15). Because the dabigatran is mainly metabolized
through the kidney (w80%), a more graded pre-
intervention termination depending on kidney function
has been proposed.
Currently, there are no data regarding when to restart
NOACs after surgical interventions. Generally, NOACs could
be restarted 24 hours post procedures with low-bleeding
risk, and 48e72 hours after procedures with high-bleeding
risk.141,188,189 However, for procedures in which immediate
and complete hemostasis can be achieved (e.g. pacemaker
implantations and skin surgery), NOACs can be resumed
6e8 hours after the interventions.141,188,189 The strategy
should be individualized for each patient because the sur-
gical process can be very different from one patient to
another, and only the surgeon responsible for the inter-
vention is able to weigh the risk of bleeding and thrombo-
embolic events accurately.
Recommendations
 Bridging with LMWH or UFH is not necessarily for
warfarin-treated patients undergoing planned sur-
gical intervention.
 Bridging with LMWH or UFH is not necessarily for
NOAC-treated patients undergoing planned surgical
intervention.
 When surgical procedures carry no clinically impor-
tant bleeding risk, these procedures can be sched-
uled at the trough concentration of the NOACs
without interruption, and NOACs could be prescribed
4e6 hours postprocedure if complete hemostasis is
achieved.
 When surgical procedures carryminor (low) ormajor
(high) bleeding risk, the time from the interruption
of NOACs to the surgical procedures depends on the
risk of bleeding and the renal function.
 Generally, NOACs can be restarted 24 hours post-
procedure with low-bleeding risk, and 48e72 hours
postprocedure with high-bleeding risk.
 For procedures in which immediate and complete
hemostasis can be achieved (e.g. pacemaker im-
plantations and skin surgery), NOACs can be resumed
6e8 hours after the interventions.
Table 15 Last intake of non-vitamin K antagonist oral anticoagulants prior to elective surgical intervention.
Dabigatran Rivaroxaban, apixaban, edoxaban
Low bleeding risk High bleeding risk Low bleeding risk High bleeding risk
CCr  80 mL/min  24 hours  48 hours  24 hours  48 hours
CCr 50e80 mL/min  24 hours  48 hours  24 hours  48 hours
CCr 30e50 mL/min  48 hours  96 hours  24 hours  48 hours
Adapted from Heidbuchel et al141 and Schulman et al.331.
CCr Z creatinine clearance rate.
Recommendations
 In patients who have been treated with NOAC for at
least 3 weeks, electrical or pharmacological car-
dioversion can be performed in a similar way as
under warfarin. After cardioversion, continuous
NOAC is mandatory for at least another 4 weeks,
irrespective of CHA2DS2-VASc score.
 In OAC-naive patients who have an AF duration of
 48 hours, there are insufficient data on safe sub-
stitution of LMWH/UFH with NOACs. Therefore,
LMWH/UFH should be given and followed by TEE to
exclude atrial thrombus.
 In OAC-naive patients who have an AF duration
> 48 hours, 2 strategies can be chosen. If early
cardioversion is attempted, NOACs should be started
for 4 hours prior to cardioversion, followed by TEE to
exclude atrial thrombus. If late cardioversion is
attempted, NOACs can be given for 3 weeks with
ensured compliance, and followed by cardioversion.
 After cardioversion, continuous NOAC is mandatory
for at least another 4 weeks, irrespective of
CHA2DS2-VASc score. Long-term use of NOACs de-
pends on the CHA2DS2-VASc score.
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In patients who have been treated with NOAC for at least
3 weeks, EC can be performed in a similar way as under
warfarin. This is based on the subgroup analyses from NOAC
trials,190e192 and the recent X-VeRT trial.193 If the compli-
ance of patients on NOAC is in doubt, TEE can be performed
prior to cardioversion. After cardioversion, continuous
NOAC is mandatory for at least another 4 weeks, irre-
spective of CHA2DS2-VASc score.
141
In OAC-naive patients who have an AF duration of
 48 hours, there are insufficient data on safe substitution
of LMWH/UFH with NOACs. Therefore, LMWH/UFH should
be given and followed by TEE. If no thrombus is found in the
atria, cardioversion can be done and NOAC should be given
for another 4 weeks. In OAC-naive patients who have an AF
duration > 48 hours, two strategies can be chosen. If early
cardioversion is attempted, NOACs should be started for
4 hours prior to cardioversion, followed by TEE to exclude
atrial thrombus. If late cardioversion is attempted, NOACs
can be given for 3 weeks with ensured compliance, and
followed by cardioversion. Similarly, continuous NOAC aftercardioversion is mandatory for at least another 4 weeks,
irrespective of CHA2DS2-VASc score.
141 Long-term use of
NOACs depends on the CHA2DS2-VASc score.9.8.9. Periablation procedure
Because catheter manipulation during ablation may
dislodge preexisting thrombi, it is important to minimize
the risk of LA thrombus formation prior to the procedure.194
International guidelines recommend at least 3 weeks of
therapeutic anticoagulation prior to ablation in all except
the lowest-risk AF patients.195 By contrast, PV isolation
(PVI) constitutes an intervention with a risk of serious
bleeding. Tamponade or hemothorax was reported to be
around 1.3% in the worldwide AF ablation registry.196
All patients undergoing AF ablation who present in AF for
the procedure should be anticoagulated for at least 3 weeks
prior to AF ablation.197 If they have not been anti-
coagulated prior to ablation, a TEE should be performed.197
International consensus or guidelines recommend per-
forming PVI in VKA-treated patients without VKA interrup-
tion.57,195 This recommendation was supported by a recent
928 C.-E. Chiang et al.RCT.198 We recommend uninterrupted warfarin use with a
target INR of 2.0e2.5 in these guidelines.
There are many reports on outcomes of PVI patients
under NOAC therapy.141 Meta-analyses of three NOACs have
demonstrated similar thromboembolic and bleeding rates
compared with uninterrupted VKAs.199e201 The first RCT on
this aspect, the Venture-AF trial, showed similar event
rates in patients on uninterrupted rivaroxaban compared
with uninterrupted VKA.202 We recommended that a last
intake of NOACs be 24 hours prior to the procedure,
although a continued intake until the evening prior to the
procedure or even the morning of the procedure seems to
be equally safe, especially in experiences centers.141
During the PVI procedure, all patients should receive full
anticoagulation with intravenous heparin, and an activated
clotting time of 300e350 seconds is recommended.197
After the ablation procedure, anticoagulants should be
initiated. In those patients who discontinued a VKA or had a
low INR at the time of ablation, LMWH should be adminis-
tered at 4e6 hours once hemostasis has been achieved,
along with reinitiating VKA, maintaining the administration
of LMWH until INR reach 2.0e3.0.197 In those patients in
who the procedure has been performed with brief inter-
ruption of a NOAC, the next dose should be administered
after 3e4 hours once hemostasis has been achieved.197 Oral
OAC, either a VKA or a NOAC, should be continued for at
least 2 months after ablation, because the vast majority of
thromboembolic events occurs in the first 4 weeks after
ablation.203Recommendations
 All patients undergoing AF ablation who present in
AF for the procedure should be anticoagulated for at
least 3 weeks prior to AF ablation. If they have not
been anticoagulated prior to ablation, a TEE should
be performed to exclude atrial thrombus.
 In warfarin-treated patients, we recommend unin-
terrupted warfarin use with a target INR of 2.0e2.5
prior to PVI.
 In NOAC-treated patients, we recommend uninter-
rupted NOAC use prior to PVI.
 During the PVI procedure, all patients should receive
full anticoagulation with intravenous heparin, and
an activated clotting time of 300e350 seconds is
recommended.
 Oral OAC, either warfarin or a NOAC, should be
continued for at least 2 months after ablation. Long-
term use of NOACs depends on the CHA2DS2-VASc
score.
Table 16 Management strategy of bleeding on non-
evitamin K antagonist oral anticoagulant (NOAC).
Review 1. Stop NOAC and antiplatelets,
review history of last dose of NOAC
2. Review drug history: NSAID,
COX-2 inhibitors, P-gp inhibitors,
CYP3A4 inhibitors
3. Check vital signs and maintain
organ perfusion
4. Check baseline laboratory data,
including CBC, platelet count,
renal and liver function, PT, aPTT
5. Check source of bleeding
Remove 1. Gastric lavage
2. Oral charcoal
3. Dialysis (only for dabigatran)
Repair 1. Assess the need for surgery to
stop bleeding
Reverse 1. Idarucizumab (for dabigatran)
2. 4-factor PCC
3. Platelet transfusion
(for thrombocytopenia)
Modified from Kovacs et al165 with permission.
aPTT Z activated partial thromboplastin time;
CBC Z complete blood count; COX-2 Z cyclooxygenase-2;
CYP Z cytochrome P450; NSAID Z non-steroidal anti-
inflammatory drugs; PCC Z prothrombin complex concen-
trate; P-gp Z P-glycoprotein; PT Z prothrombin time.9.8.10. Management of bleeding complications
It has been shown that the use of NOACs in Asians is more
effective and much safer than warfarin.149,150 The more
serious bleeding events, such as ICH and hemorrhagic
stroke, were much less common in patients on NOACs than
in patients on warfarin.150 Even in patients with
anticoagulant-related ICH, the hematoma volume wasmuch smaller and the prognosis was much better in the
NOAC-users compared with warfarin users.204 As more pa-
tients start using NOACs, the number of bleeding events is
expected to increase.
A proposed management strategy of bleeding in patients
on NOACs was shown in Table 16.165 The first thing is to stop
NOACs immediately and follow the strategy. Since the
elimination half-lives of most NOACs are relatively short,
time is the most important antidote of NOACs. After
cessation of treatment, restoration of hemostasis is to be
expected within 12e24 hours after the last taken dose,
given plasma half-life of around 12 hours for most
NOACs.141 The drug history should be evaluated in every
patient, as increased medication number was associated
with the risk of bleeding.103,104,205 In patients with non-
elife-threatening bleeding, standard supportive care will
be enough. In case of bleeding in patients on dabigatran,
adequate diuresis must be maintained. Although dabigatran
can be dialyzed, there is limited clinical experience in using
dialysis in this setting.141 Dialysis is not expected to
significantly reduce the plasma level of factor X inhibitors
due to their high plasma binding and limited renal
excretion.141
In patients encountering life-threatening bleeding, more
aggressive management is suggested. In patients treated
with dabigatran, idarucizumab is the preferred reversal
agent.156 The efficacy of PCC and aPCC in patients who are
actively bleeding has not been firmly established, although
animal studies have shown their efficacy in normalizing
anticoagulation parameters.141 Nevertheless, the
Recommendation
 Percutaneous LAA closure may be considered in pa-
2016 AF Guidelines of THRS/TSOC 929administration of PCC or aPCC can be considered in patients
with life-threatening bleeding if immediately hemostasis is
required.141 Fresh frozen plasma cannot reverse anti-
coagulation in patients on NOACs, but may be used to
expand plasma volume as a supportive care. Vitamin K
administration has no role in the management of bleeding
event due to NOACs.141Recommendations
 When encountering bleeding events, the first thing is
to stop NOACs immediately. After cessation of
NOAC, restoration of hemostasis is to be expected
within 12e24 hours after the last taken dose.
 In patients with nonelife-threatening bleeding,
standard supportive care will suffice.
 In patients encountering life-threatening bleeding
with the use of dabigatran, idarucizumab is the
preferred reversal agent.
 The administration of PCC or aPCC can be consid-
ered in patients with life-threatening bleeding if
immediate hemostasis is required.
 Fresh frozen plasma cannot reverse anticoagulation
in patients on NOACs, but may be used to expand
plasma volume as a supportive care.
 Vitamin K administration has no role in the man-
agement of bleeding event under NOACs.
tients with a very high stroke risk and absolutely
contraindicated for long-term OAC.9.9. Left atrial appendage closure
It is generally believed that the LAA is the main (but not the
only) source of thrombi formation that induce ischemic
stroke in AF patients.92,206 Observational studies have
shown inconsistent results of surgical LAA excision or oc-
clusion.207 Two self-expanding devices, the WATCHMAN and
the Amplatzer Cardiac Plug, which are trans-septally
placed in the LAA, are available for clinical use. The PRO-
TECT AF trial randomized 707 patients either to percuta-
neous closure of the LAA, using the WATCHMAN devices, or
to OAC (INR range 2.0.3.0).208 Patients randomized to LAA
occlusion were treated with OAC for 45 days after the
procedure, followed by DAPT for 6 months and aspirin alone
as chronic therapy. The early findings for the WATCHMAN
device suggested noninferiority to warfarin for the com-
posite endpoint of stroke, SEE, and CV death; however,
early adverse events occurred in about 10% of patients.208
The Continued Access to PROTECT AF registry was
following patient outcomes beyond the end of enrolment
and demonstrated a learning curve effect with reduced
complication rates after the end of the trial.209 Data from
the PREVAIL trial found that the earlier device-related
complications were mitigated with increasing operator
experience.210 In 2015, US FDA approved the use of the
WATCHMAN device for the prevention of stroke in patients
with AF.
The initial experience with the Amplatzer Cardiac Plug
appears promising, with 97% acute obliteration of the
LAA.211 The long-term outcomes of the use of this device,requiring RCTs to study reduced stroke risk and safety, are
not yet defined.10. Rate versus rhythm control
It is generally believed that AF patients have deleterious
outcomes compared with those in sinus rhythm and sinus
rhythm maintenance should be better. On one hand, out-
comes of virtually all rate versus rhythm trials have shown
no such advantage (Figure 15). A recent meta-analysis of
five clinical trials suggests a trend towards increased mor-
tality and stroke with rhythm control.212 A post hoc analysis
of the AFFIRM database showed a 47% reduction in mor-
tality among patients who remained in sinus rhythm during
the study, but this benefit was possibly nullified by the 49%
increase in mortality conferred by antiarrhythmic drugs
(AADs).213 Furthermore, when applied in patients who were
candidates for both treatment strategies, a rhythm-control
strategy resulted in more hospitalizations.214 Therefore, a
routine use of rhythm strategy is not warranted for some
patients. On the other hand, rhythm-control strategy is
associated with improvements in symptoms and quality of
life in some patients,215,216 while persistent symptoms
remain the most compelling indication for a rhythm-control
strategy.92 Early initiation of rhythm-control strategy can
also prevent progression of AF.56,217,218
The only randomized trial comparing rhythm versus rate
control in an eastern population is the J-Rhythm trial.219 In
this trial, although the rhythm-control strategy was supe-
rior to rate control where the primary endpoints were
concerned, there was no difference when hard endpoints,
such as mortality, embolization, bleeding, and heart failure
were taken into account. Furthermore, J-Rhythm included
low-risk patients: only 42.8% of the population had hyper-
tension, 7.4% had coronary artery disease, and 3.6% had
heart failure. The vast majority, 78.1%, had a CHADS2 score
of 0 or 1. This does not reflect the complicated AF patients
seen in daily practice.32,214
Since there is no evidence suggesting a preferred strat-
egy, the management of AF should be individualized. The
initial therapy after onset of AF should always include
adequate antithrombotic treatment and control of the
ventricular rate (Figure 2). If the ultimate goal is restora-
tion and maintenance of sinus rhythm, rate-control medi-
cation should be continued throughout follow-up, unless
continuous sinus rhythm is present.57 The goal is to control
the ventricular rate adequately whenever recurrent AF
occurs.57 Symptoms related to AF are an important deter-
minant in making the decision to choose for rate or rhythm
control. Rhythm-control strategy is recommended in pa-
tients with symptomatic (EHRA  2) AF despite adequate
rate control. Other factors that may favor attempts at
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Figure 15 Cardiovascular outcomes of randomized controlled trials of comparing rhythm- versus rate-control strategies.
930 C.-E. Chiang et al.rhythm-control strategy include difficulty in achieving
adequate rate control, younger patients, tachycardia-
mediated cardiomyopathy, first episode of AF, AF precipi-
tated by an acute illness, and patient preference.92Recommendations
 Rate-control strategy can be applied in patients with
minor symptoms (EHRA score I).
 Rate-control strategy should be continued
throughout a rhythm-control strategy to ensure
adequate control of ventricular rate during re-
currences of AF.
 Rhythm-control strategy is recommended in patients
with symptomatic (EHRA  2) AF despite adequate
rate control.
 Some factors may favor attempts at rhythm-control
strategy, such as difficulty in achieving adequate
rate control, younger patients, tachycardia-
mediated cardiomyopathy, first episode of AF, AF
precipitated by an acute illness, and patient
preference.11. Rate-control strategy
11.1. Acute rate control
The acute management of patients with AF is driven by
relief of symptoms and acute improvement of cardiac
function. The initial assessment should include a careful
clinical and medicinal history. Comorbidity and LV function
should be noticed in the initial pharmacological manage-
ment of AF. AF occurring in a patient with Wolf-
feParkinsoneWhite syndrome is a dangerous situation
because rapid atrioventricular (AV) conduction through the
accessory pathway may precipitate ventricular fibrillation.
Identification of pre-excited AF is critical and should be
considered with any rapid (200e300 bpm) sustained, highlyirregular wide QRS-complex tachycardia. In these patients,
drugs that block AV conduction (digoxin, b-blockers,
calcium-channel blockers, and adenosine) are contra-
indicated because they do not slow conduction through the
accessory pathway and may precipitate VF.
The severity of AF-related symptoms will decide the
acute restoration of sinus rhythm (if symptomatic hypo-
tension, angina, or heart failure is present) or acute control
of the ventricular rate. The duration of AF and risk of
thromboembolic events are other important initial con-
cerns. The initial management of symptomatic AF may
differ from one patient to another. For patients with
symptomatic AF lasting many weeks, initial therapy may be
anticoagulation and rate control. For patients with new-
onset AF for < 48 hours, initial therapy may be pharma-
cological cardioversion or EC,220 combined with antith-
rombotic therapy if indicated.
The 2010 European guidelines suggest the target ven-
tricular rate should usually be 80e100 bpm in the acute
setting.57 The Canadian guidelines suggest physician should
attempt to reduce the heart rate prior to discharge from
the emergency department to target rates of < 100 bpm at
rest159 and < 110 bpm during moderate exercise (such as
walk test).221 However, there is no prospective, random-
ized, placebo-control study solving this issue, and the
optimal level of ventricular rate in the acute rate control of
AF remains unknown and deserves further study.
An inappropriate ventricular rate and irregularity of the
rhythm can cause symptoms and compromise hemodynamic
conditions in AF patients. Patients with rapid ventricular
response usually need acute control of their ventricular
rate. Recommended intravenous drugs for acute rate con-
trol are shown in Table 17. In stable patients, this can be
achieved by oral administration of b-blockers or non-
dihydropyridine (non-DHP) calcium-channel antagonists.
Verapamil should not be used in patients with decom-
pensated heart failure as it may lead to further hemody-
namic compromise. In selected patients, intravenous
amiodarone or digoxin may be used, especially in those
with severely depressed LV function, heart failure, or hy-
potension.92,222 However, intravenous amiodarone should
not be used in the case of pre-excited AF.92,223,224
Table 17 Recommended intravenous drugs for acute rate control of atrial fibrillation.
Drug Dose Adverse effects
Diltiazema 0.25 mg/kg IV bolus over 2 min;
a second dose in 15 min if necessary
Hypotension, bradycardia, AV block, asystole
Verapamila 0.075e0.15 mg/kg over 2 min;
a second dose may be given
30 min later if necessary
Hypotension, bradycardia, AV block, asystole
Propranolol 0.25e1 mg IV every 5 min;
no more than 0.2 mg/kg in total
Hypotension, bradycardia, AV block, asystole,
congestive heart failure
Esmolol 50e250 mg/kg/min IV infusion Hypotension, bradycardia, congestive heart failure
Landiolol 1e10 mg/kg/min Hypotension, bradycardia, congestive heart failure
Amiodarone 15 mg/min for 10 min; then 1 mg/min
for 6 h, and 0.5 mg/min thereafter
Hypotension, bradycardia, congestive heart failure
Digoxin 0.25 mg IV every 2 h; up to 1 mg Bradycardia, AV block, digitalis toxicity
AV Z atrioventricular; IV Z intravenous.
a Calcium-channel blockers or propranolol should not be used in patients with heart failure or left ventricular dysfunction.
2016 AF Guidelines of THRS/TSOC 931Combination therapy may be necessary in some intractable
patients. Acute initiation of rate control therapy should
usually be followed by a long-term rate or rhythm control
strategy.
Most patients with recent-onset AF may be stabilized in
a few hours when adequate rate or rhythm control has been
achieved. Symptomatic patients with decompensated heart
failure or angina pectoris should be hospitalized. Occa-
sionally, admission may be required for highly symptomatic
patients in whom adequate rate or rhythm control cannot
be reached.Recommendations
 Intravenous use of b-blockers or non-DHP calcium-
channel blockers is recommended to slow ventricu-
lar rate in the acute setting in patients without pre-
excitation.
 Verapamil should not be used in patients with
decompensated heart failure as it may lead to
further hemodynamic compromise.
 In selected patients, intravenous amiodarone or
digoxin may be used, especially in those with
severely depressed LV function, heart failure, or
hypotension.
 In patients with pre-excitation and AF, b-blockers,
digoxin, non-DHP calcium-channel blockers, and
intravenous amiodarone should not be used as they
may increase ventricular rate and result in ventric-
ular fibrillation.11.2. Chronic rate control
Beta-blockers, non-DHP calcium-channel blockers (diltia-
zem, verapamil), and digitalis are the primary drugs used
for ventricular rate control during AF. The choice of drugs
for rate control depends on age, underlying heart disease,
and the goal of treatment (Figure 16). In patients whoremain symptomatic on strict rate-control therapy, rhythm-
control therapy may be considered. Table 18 shows the
drugs and their dosages for rate control. All these drugs act
by slowing AV nodal conduction and prolonging AV nodal
refractoriness. Non-DHP calcium-channel antagonists
should not be used in decompensated heart failure. With
pre-excitation and AF, digoxin, non-DHP calcium-channel
antagonists, or intravenous amiodarone, should not be
administered.92,223e225 The safety of oral amiodarone in
pre-excitation AF has not been determined.
The adequacy of heart rate control should be assessed
during exertion, adjusting drug treatment as necessary to
keep ventricular rate within the physiological range. In
small, mostly blinded randomized trials, b-blockers led to
lower heart rates at rest and exercise but no change or a
decrease in exercise capacity.226 Calcium-channel blockers
were less effective at heart rate lowering on exercise but
led to an increase or no change in exercise capacity. In one
study, b-blockers added to digoxin did not result in
improved quality of life, whereas calcium-channel blockers
resulted in small improvements in physical and emotional
function.227 Digitalis prolongs AV nodal refractoriness by
enhancing vagal tone. During exercise, vagal tone is with-
drawn, and therefore digitalis controls the heart rate less
effectively than b-blockers or calcium-channel blockers.
Digitalis should thus be avoided as the sole agent in active
patients.228,229 Digoxin is generally combined with another
rate-slowing drug. Drug combinations are frequently
effective when treatment with a single agent fails. Amio-
darone has significant rate-controlling properties in addi-
tion to its antiarrhythmic actions and may be used in
refractory patients. However, because of the risk of toxicity
associated with long-term use, it should be used only when
other rate control strategies are not feasible or are
insufficient.
Long-term CV outcome trials comparing of different rate
control drugs are not available. A recent cohort study from
Taiwan NHIRD, using data of whole country AF population,
may provide some evidence for choice of different rate
control agent.230 There were 43,879, 18,466, and 38,898
patients with AF enrolled in the groups receiving b-
blockers, calcium-channel blockers, and digoxin,
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Figure 16 Choice of drugs for chronic rate control. COPD Z chronic obstructive pulmonary disease.
932 C.-E. Chiang et al.respectively. The reference group consisted of 168,678
patients who did not receive any rate-control drug. The
clinical end point was all-cause mortality. During a follow-
up of 4.9  3.7 years, mortality occurred in 88,263 pa-
tients (32.7%). After adjustment for baseline differences,
the risk of mortality was lower in patients receiving b-
blockers (adjusted HR Z 0.76; 95% CI Z 0.74e0.78) and
calcium-channel blockers (adjusted HR Z 0.93; 95%
CI Z 0.90e0.96) compared with those who did not receive
rate-control medications. On the contrary, the digoxin
group had a higher risk of mortality with an adjusted hazard
ratio of 1.12 (95% CI Z 1.10e1.14). The results were
observed consistently in subgroup analyses and among the
cohorts after propensity matching. In this nationwide AFTable 18 Drugs for chronic rate control.
Usual oral maintenance dose
b-blockers
Metoprolol CR/XL 100e200 mg once daily (ER)
Bisoprolol 2.5e10 mg once daily
Atenolol 25e100 mg once daily
Esmolol N/A
Propranolol 10e40 mg three times daily
Carvedilol 3.125e25 mg twice daily
Nondihydropyridine calcium-channel blockers
Verapamil 40 mg twice daily to
360 mg (ER) once daily
Diltiazem 60 mg three times daily to
360 mg (ER) once daily
Digitalis glycosides
Digoxin 0.125 mge0.5 mg once daily
Digitoxin 0.05 mge0.1 mg once daily
Others
Amiodarone 100 mge200 mg once daily
CR/XL Z controlled release/extended release; ER Z extended
release; N/A Z not applicable.cohort, the risk of mortality was lower in patients receiving
rate-control treatment with b-blockers or calcium-channel
blockers, and the use of b-blockers was associated with
the largest risk reduction. Digoxin use was associated with
greater mortality. Prospective, randomized trials are
necessary to confirm these findings.
The negative information about the use of digoxin has
increasingly been reported. Two separate papers from
Taiwan described an increased risk of ischemic stroke in
digoxin users versus nondigoxin users.231,232 One of them
found an increased risk of total mortality.231 In a retro-
spective analysis of the ROCKET AF trial, the use of digoxin
was associated with a significant increase in all-cause
mortality, vascular death, and sudden death in patients
with AF.233 Increased mortality was also found in a retro-
spective analysis of the AFFIRM trial,234 and an updated
meta-analysis.235 It is generally accepted that the priority
of the use of digoxin in rate control of AF should follow b-
blockers and calcium-channel blockers.Recommendations
 The adequacy of heart rate control should be
assessed during exertion, allowing adjustment of
drug treatment as necessary to keep ventricular rate
within the physiological range.
 For rate-controlling agents, b-blockers are prefer-
able in terms of long-term CV outcomes, followed by
non-DHP calcium-channel blockers, and digoxin.
 Drug combinations are frequently effective when
treatment with a single agent fails.
 In patients with pre-excitation and AF, b-blockers,
digoxin, non-DHP calcium-channel blockers, and
intravenous amiodarone should not be used as they
may increase ventricular rate and result in ventric-
ular fibrillation.
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Rate control is an important part of therapy for all patients
with AF or AFL. An irregular rhythm and a rapid ventricular
rate in AF can cause symptoms including palpitations,
dyspnea, fatigue, and dizziness. Adequate control of the
ventricular rate may reduce symptoms and improve he-
modynamics, by allowing enough time for ventricular
filling, increases in ventricular regularity, avoiding rate-
related ischemia, enhancement of intraventricular con-
duction with rate reduction, and prevention of tachycardia-
mediated cardiomyopathy. The primary goal of rate control
is to improve symptoms and prevent deterioration of car-
diac function during AF or AFL. Tachycardia-mediated car-
diomyopathy refers to a condition characterized by LV
systolic dysfunction occurring in patients with sustained
rapid heart rates. This complication can occur in some
patients with AF or AFL and very rapid ventricular rates
(e.g. > 120/min for most of the time) and is totally or
partially reversible and preventable with adequate rate
control.236,237
The optimal level of ventricular rate control with
respect to morbidity, mortality, and quality of life remains
unclear. In the past, adequate ventricular rate control was
empirically defined as < 80 bpm at rest.72,214 Strict rate-
control therapy may result in implantation of a pace-
maker for symptomatic bradycardia in 7.3% of patients in
the AFFIRM trial, while post hoc analyses of the AFFIRM and
RACE (rate control vs. EC) studies showed higher resting
heart rates were not associated with an adverse
outcome.238 The RACE II (RAte Control Efficacy in perma-
nent AF) trial randomized patients to strict (< 80 bpm at
rest and < 110 bpm during moderate exercise) or lenient
(< 110 bpm at rest) rate-control strategies.239 No differ-
ence in the primary outcome (composite of CV death, heart
failure hospitalization, stroke, systemic embolism,
bleeding, and arrhythmic events) was found between these
two strategies. Patients assigned to lenient rate controlFor any type of a trial fibrillaƟon
lenient rate control: resƟng HR < 100 bpm
If symptomaƟc 
Rhythm control
if feasible
Strict rate control:
resƟng HR < 80 bpm and 
HR during moderate exercise < 1
Pharmacological management
If
Figure 17 Flow chart of chronic rate contachieved the goal of rate control in a larger proportion of
patients with lower drug doses and fewer combinations of
drugs, and had fewer hospital visits. Further analysis of
RACE II data, even in patients with successful strict rate
control, strict rate control still cannot identify a benefit in
outcomes over lenient rate-control therapy.240 Therefore,
in patients without severe symptoms due to a high ven-
tricular rate, lenient rate control might be frontline strat-
egy. Relatively few patients randomized to lenient rate
control had resting heart rates > 100e110 bpm. Further-
more, at the end of the first year, average resting heart
rates were 85  13 bpm, 78  12 bpm, and 75  14 bpm in
the lenient, failed strict rate control and successful strict
rate control arms, respectively. Since few patients had
resting heart rates > 100 bpm in the RACE II trial, and
previous studies cannot conclusively show the safety of
resting heart rates >100 bpm, we recommend that a heart
rate target of <100 bpm at rest is appropriate for most
patients.
Lenient rate control (resting heart rate < 100 bpm)
should be the initial approach in patients with AF and minor
symptoms. Rate control should continue throughout a
rhythm control therapy to ensure adequate ventricular rate
during recurrences of AF. Rhythm control should be
considered in patients with symptomatic AF despite of
adequate rate control.241 A strict rate-control (resting
heart rate < 80 bpm) strategy is reasonable when symptoms
persist or tachycardia-mediated cardiomyopathy occurs.
After achieving the strict heart rate target, a exercise test
and/or 24-hour Holter ECG are recommended to assess the
chronotropic response during exertion and to avoid brady-
cardia. AV nodal ablation with permanent ventricular pac-
ing is reasonable when pharmacological management is
inadequate and rhythm control is not achievable. AV nodal
ablation should not be performed without prior attempts to
achieve rate control with medications. A flow chart of the
recommended approach to long-term rate control is shown
in Figure 17.10 bpm
Ablate and pace
 symptomaƟc 
rol. HR Z heart rate (beats/min, bpm).
Recommendations
 Lenient rate control (resting heart rate < 100 bpm)
should be the initial approach in patients with AF
and minor symptoms.
 A strict rate control (resting heart rate < 80 bpm)
strategy is reasonable when symptoms persist or
tachycardia-mediated cardiomyopathy occurs.
 After achieving the strict heart rate target, an ex-
ercise test and/or 24 hour Holter ECG are recom-
mended to assess the chronotropic response during
exertion and to avoid bradycardia.
934 C.-E. Chiang et al.12. Rhythm-control strategy
12.1. Electric cardioversion
EC is an alternative strategy for the management of pa-
tients with AF when rhythm control is appreciated. Ac-
cording to a real-world survey conducted by the EHRA,
67.9% of the study sites preferred EC.242 Randomized
studies support the efficacy and safety of EC such as
RACE,243 STAF,244 and HOT CAFE.245 However, this method
is performed most frequently in patients with symptomatic
or newly diagnosed AF.
Conversion of AF to sinus rhythm could result in transient
mechanical stunning of the LA and LAA that could have a
risk of thromboembolism. Based on the Finnish CardioVer-
sion Study,246 the thromboembolic events are < 1% within
30 days after cardioversion of acute AF, even without per-
iprocedural anticoagulation. However, the thromboembolic
risk increased to 9.8% among patients with heart failure and
diabetes. Under this context, anticoagulation is mandatory
in cardioversion of AF if AF duration is > 48 hours orHemodynamic instability
Heparin
AF for electrical cardioversion
Yes
Cardioversion
Yes
Therapeu
for 3
Heparin
If LA/L
presen
term OA
TherapeuƟc OAC
for 4 wks
Consider long-term OAC
if CHA2DS2-VASc score ≥ 1
Figure 18 Management algorithm of electrical cardioversion. A
appendage; OAC Z oral anticoagulant; TEE Z transesophageal ecunknown.57,72 VKA treatment to keep INR 2.0e3.0, or a
NOAC should be given for at least 3 weeks prior to EC and
the VKA or NOAC should be continued for a minimum of
4 weeks after EC. In patients with risk factors for stroke or
AF recurrence, VKA or NOAC treatment should be continued
lifelong irrespective of sinus rhythm restoration after EC. A
management algorithm was shown in Figure 18.
TEE-guided cardioversion is an alternative method to
3 weeks’ precardioversion anticoagulation when early car-
dioversion is needed. If no LA or LAA thrombus was detec-
ted on TEE, heparin or a NOAC should be started prior to the
EC and continued after the procedure. If TEE found
thrombus in LA or LAA, VKA treatment to keep INR at
2.0e3.0 or a NOAC are required for at least 3 weeks and TEE
should be repeated and EC could be performed if the
thrombus resolution is completed. If thrombus is still pre-
sent, the rate control strategy should be considered.
In hemodynamic instability, immediate EC should be
performed, and heparinization (UFH or LMWH) should be
administered prior to EC. After that, heparin should be
continued, combined with VKA, until the INR is at the
therapeutic level (2.0e3.0). A NOAC can be used too. If AF
duration is < 48 hours, EC can be performed directly under
the cover of intravenous UFH, followed by infusion or sub-
cutaneous LMWH. In patients with a CHA2DS2-VACs  1, VKA
or NOAC should be continued indefinitely.
The immediate success rate varied from 70% to 99% and
the complete shock failure or immediate recurrence
occurred in approximately 25% of patients undergoing EC of
AF. Many randomized studies support that pretreatment
with AADs such as amiodarone, ibutilide, sotalol, flecai-
nide, and propafenone could increase the success rate.247
Recent evidence supports the use of biphasic external
defibrillators for AF cardioversion because of their lower
energy requirement and greater efficacy compared to
monophasic defibrillators.248 An initial energy of 200 J or
greater is recommended for conversion of AF withAF onset < 48 h
No
OAC or TEE guided
No
Ɵc OAC
 wks
TEE guided
No LA/LAA 
thrombus
LA/LAA 
thrombus
TherapeuƟc OAC
for 3 wks
AA thrombus sƟll 
t, consider long-
C and rate control
F Z atrial fibrillation; LA Z left atrium; LAA Z left atrial
hocardiography.
Recommendations
 In patients without structural heart diseases, Class
IC drugs, such as propafenone and flecainide, can be
used for pharmacological cardioversion of recent-
onset AF.
 In patients with severe structural heart diseases,
such as history of MI, CHD, heart failure, severe LV
hypertrophy, and hemodynamically significant
valvular diseases, Class IC AADs cannot be used.
 In patients with recent-onset AF and structural heart
2016 AF Guidelines of THRS/TSOC 935monophasic waveform and a similar recommendation to
start with 200 J using biphasic waveforms.
The anterioreposterior paddle position was associated
with a significantly higher successful conversion rate and
lower cumulative energy requirement as compared with
anteriorelateral position.249 Short-acting anesthesia
agents, such as midazolam, fentanyl, and propofol, are
frequently used due to their rapid onset and short half-
life. The shocks should be delivered in a synchronized
fashion in order to avoid shock during the vulnerable
phase of cardiac cycle (shock on T wave) and subsequent
ventricular fibrillation. For patients with an implanted
device, the anterioreposterior paddle position is recom-
mended and the paddle should be placed as far as possible
and at least 8 cm from the pacemaker battery to reduce
the potential risk.
The major risks and complications of cardioversion are:
(1) risks associated with sedation; (2) thromboembolic
events; and (3) postcardioversion arrhythmias. The pro-
cedure is associated with 1e5% risk of thromboembolism
and could be reduced by adequate anticoagulation. Serious
arrhythmias such as ventricular tachycardia and fibrillation
may occur in the presence of hypokalemia, digitalis intox-
ication, or improper synchronization.Recommendations
 In AF duration is > 48 hours or unknown, warfarin
treatment to keep INR 2.0e3.0, or a NOAC, should
be given for at least 3 weeks prior to EC.
 The TEE-guided cardioversion is an alternative
method to 3 weeks’ precardioversion anti-
coagulation when early cardioversion is needed.
 If AF duration is < 48 hours, EC can be performed
directly under the cover of intravenous UFH, fol-
lowed by infusion or subcutaneous LMWH.
 Warfarin or NOAC should be continued for a mini-
mum of 4 weeks after EC.
 In patients with a CHA2DS2-VACs  2, warfarin or
NOAC should be continued indefinitely, irrespective
of sinus rhythm restoration after EC.
disease, intravenous amiodarone is recommended
for pharmacological cardioversion.12.2. Acute pharmacological cardioversion
Pharmacological cardioversion is most likely successful
when initiated within 7 days after onset of an episode of
AF. Although there are several drugs available for this
purpose, only three AADs are available in Taiwan: amio-
darone, propafenone, and flecainide. Intravenous amio-
darone has more potent b-blocking effect than its Class III
drug effect. Therefore, its effect in converting AF to sinus
rhythm is usually delayed, slower than oral loading of
Class IC drugs, such as propafenone or flecainide.250,251 In
the SAFE-T trial,215 only 25% of patients with persistent AF
were converted by oral amiodarone. Oral propafenone
(600 mg) or flecainide (300 mg) are more effective than
amiodarone in conversion of AF to sinus rhythm,251 butthis should be done in a monitored condition in the first
attempt, since bradycardia or other proarrhythmia may
occur. A b-blocker and/or non-DHP calcium-channel
blocker should be administered at least 30 minutes prior
to the loading of these Class IC AADs to avoid catastrophic
AFL with 1:1 AV conduction.92 In patients with severe
structural heart diseases, such as history of MI, CHD, heart
failure, severe LV hypertrophy, and hemodynamically
significant valvular diseases, Class IC AADs cannot be
used.7212.3. Chronic rhythm control
When a rhythm-control strategy is undertaken, AADs should
be selected to reduce the frequency and duration of AF and
improve quality of life. Once AAD is initiated, patients’
symptoms may improve without complete suppression of
AF. Well-tolerated recurrence of AF is a reasonable
outcome and should not be called treatment failure.72
In the choice of AADs for rhythm control, safety concern
seems more important than drug efficacy. A notorious side
effect of AADs is the proarrhythmic effect: the exacerba-
tion of a previous arrhythmia or the onset of a new, more
serious (or even lethal) arrhythmia caused by the use of an
individual AAD.31 Because proarrhythmias can occur at
serum levels below or within the therapeutic range, they
cannot be accurately predicted by blood sampling.31 Two
important proarrhythmia effects are ventricular tachy-
cardia/ventricular fibrillation, and drug-induced long QT
syndrome/torsade de pointes.31 In the Cardiac Arrhythmia
Suppression Trial (CAST), the use of Class IC drugs including
flecainide and encainide in patients in the convalescent
state of MI resulted in a 2.5-fold increase in mortality
compared with placebo.252 Thereafter, Class IC drugs were
contraindicated in patients with acute MI, and also con-
traindicated in moderate to severe structural heart dis-
eases, such as ischemic heart disease, heart failure,
valvular heart disease, cardiomyopathy, and hypertension
with severe LV hypertrophy.57 Long QT syndrome can be
caused by Class IA and Class III AADs. In a meta-analysis of
44 trials, AADs significantly reduced recurrence of AF, but
all increased proarrhythmias, except amiodarone and
propafenone.253 Class IA AADs were associated with
936 C.-E. Chiang et al.increased mortality compared with controls, similar to a
previous report.254
Most AADs, including Class IA, Class IC, and Class III
agents, can reduce the risk of recurrence by 50e70% in
1 year.255 The efficacy of sotalol in the prevention of
recurrence of AF is similar to that of propafenone.256 In the
Sotalol Amiodarone atrial Fibrillation Efficacy Trial (SAFE-
T), the efficacy of sotalol in maintaining sinus rhythm was
not inferior to that of amiodarone in the subgroup of pa-
tients with ischemic heart disease.215
12.3.1. Amiodarone
When it comes to preventing the recurrence of AF,
amiodarone is the most effective drug; better than
sotalol and propafenone.215,256 In a mixed treatment
comparison of amiodarone, dronedarone, sotalol, prop-
afenone, and flecainide, amiodarone was the most
effective to reduce recurrence of AF.257 Nevertheless,
amiodarone has not been shown to decrease mortality or
stroke compared with other treatments or with pla-
cebo,215,256 and it has not been shown to reduce the risk
of hospitalization.258 Patients with New York Heart As-
sociation Functional Class III heart failure who received
amiodarone had a 44% increase in mortality comparing
with those receiving placebo in the SCD-HeFT trial259;
however, amiodarone can generally be safely used in
patients with structural heart disease.260 Because of
multichannel blocking activity, the risk of torsade de
pointes associated with amiodarone is lower than that
with pure potassium channel blockers. In patients with LV
hypertrophy, heart failure, CHD, previous MI, amiodarone
is associated with a low risk of proarrhythmias, making it
an appropriate initial choice to prevent AF recurrence in
these clinical settings.92
12.3.2. Dronedarone
Dronedarone is a benzofuran derivative, structurally
related to amiodarone. It is structurally different from
amiodarone in two key ways: the two iodine atoms have
been deleted and aliphatic side chains have been added.
These structural changes have markedly decreased the
thyroid toxicity and shortened its half-life. As with
amiodarone, dronedarone is a multichannel blocker and
has a very low risk for torsade de pointes, probably due
to three mechanisms: the reduction of dispersion in
transmural repolarization; the lack of reverse use-
dependent effect; and the ability to abolish early after-
depolarizations.31
Dronedarone is more effective in maintaining sinus
rhythm than placebo,261 but is inferior to amiodarone in
that aspect.262 The efficacy of dronedarone in reducing
CV outcomes was demonstrated in the ATHENA trial, in
which 4628 high-risk patients with paroxysmal or persis-
tent AF were randomized to dronedarone 400 mg twice a
day or placebo.263 After a mean follow-up of 21 months,
patients taking dronedarone experienced a 24% reduction
(p < 0.001) in the combined primary endpoints, which
included CV hospitalization and total death. The three
secondary endpoints were also reduced: there was a 26%
reduction in CV admission (p < 0.001), a 29% reduction inCV mortality (p Z 0.03), and a 16% reduction in all-cause
mortality (p Z 0.18). The post hoc analysis also revealed
a 34% reduction in stroke (p Z 0.027).264 Serious adverse
events were similar in both groups.263 The ATHENA trial
has established the preferential role of dronedarone in
the treatment of AF, but dronedarone should not be used
in patients with New York Heart Association Functional
Class II to IV heart failure who have had recent decom-
pensation. In the ANDROMEDA trial, when such patients
received dronedarone, the rate of total mortality
increased roughly two-fold in just 2 months, resulting in
premature termination of the trial.265
The effect of dronedarone has also been tested in
patients with permanent AF. In the PALLAS trial, patients
with permanent AF and CV risk factor were randomized
to dronedarone 400 mg twice daily and matching pla-
cebo.266 The trial was prematurely terminated due to an
increase in CV events, including CV death, in the drone-
darone arm compared with the placebo arm. Stroke and
hospitalization for heart failure were also increased. The
reason for the results of the PALLAS trial being
completely opposite to those in the ATHENA trial was not
entirely clear. The PALLAS trial enrolled a high proportion
of patients with heart failure and a high percentage of
patients taking digoxin. Therefore, AF patients with
permanent form or with a history of heart failure should
not be given dronedarone. The combined use of drone-
darone with digoxin is not recommended. A flowchart of
the selection of the rhythm control drugs is shown in
Figure 19.
12.4. “Pill-in-the-pocket” strategy
Another way to pharmacological cardioversion for pa-
tients with infrequent but symptomatic attack is the
“pill-in-the-pocket” strategy.267,268 Oral flecainide
(300 mg) or propafenone (600 mg) were given to restore
sinus rhythm in 268 patients with mild heart disease or
none who came to the emergency room with AF of recent
onset that was hemodynamically well tolerated.267 Out-
of-hospital self-administration of flecainide or prop-
afenonedthe “pill-in-the-pocket” approachdafter the
onset of heart palpitations was evaluated. Treatment was
successful in 94% in a mean follow-up of 15 months. The
time to resolution of symptoms was 113 minutes. The
numbers of monthly visits to the emergency room and
hospitalizations were significantly lower during follow-up
than during the year prior to the target episode. Only one
patient had AFL with a rapid ventricular rate. This study
suggested that in a selected population of patients with
recurrent AF, “pill-in-the-pocket” treatment is feasible
and safe, with a high rate of compliance by patients, a
low rate of adverse events, and a marked reduction in
emergency room visits and hospital admissions. The
initial attempt should be in a monitored condition before
this approach is used in the unmonitored outpatient
setting.92 A b-blocker or non-DHP calcium-channel
blocker should be administered  30 minutes prior to
these Class IC drugs to prevent a rapid ventricular
response due to 1:1 AV conduction during AFL.92
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Figure 19 Flow chart of the selection of the rhythm control drugs. CAD Z coronary artery disease; HT Z hypertension;
LVH Z left ventricular hypertrophy. (Modified from Chiang et al.31 with permission.)
Recommendations
 Amiodarone is more effective in maintaining sinus
rhythm than propafenone, flecainide, sotalol, and
dronedarone.
 For patients with heart failure, amiodarone is the
drug of choice for maintaining sinus rhythm.
 In patients with severe structural heart diseases,
such as history of MI, CHD, heart failure, several LV
hypertrophy, and hemodynamically significant
valvular diseases, Class IC AADs cannot be used.
 In patients without significant structural heart dis-
ease, initial antiarrhythmic therapy should be cho-
sen from dronedarone, flecainide, propafenone, and
sotalol.
 Dronedarone should be considered in patients with
nonpermanent AF and CV risk factors to reduce CV
hospitalizations and total mortality.
 Dronedarone should not be used in patients with
heart failure.
 Dronedarone should not be used in patients with
permanent AF.
 Dronedarone should not be combined with digoxin.
Recommendations
 In selected patients without significant structural
heart disease, a single high oral dose of flecainide or
propafenone (the “pill-in-the-pocket” approach)
can be considered for infrequent but symptomatic
attack of AF, provided this treatment has proven
safe during previous testing in a medically secure
environment.
 A b-blocker or non-DHP calcium-channel blocker
should be administered  30 minutes prior to the
“pill-in-the-pocket” approach to prevent a rapid
ventricular response due to 1:1 AV conduction during
AFL.
2016 AF Guidelines of THRS/TSOC 93712.5. Upstream therapy
Upstream therapy refers to the use of noneion-channel
antiarrhythmic drugs that modify the atrial substrate to
prevent the occurrence of new onset AF (primaryprevention) or recurrence of the arrhythmia (secondary
prevention). Potential intervention mainly includes
angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin-receptor blockers (ARBs), statins, and fish oil.
12.5.1. ACEIs and ARBs
Several retrospective post hoc analyses from large RCTs
have reported a sustained reduction in new-onset AF
(i.e. primary prevention) with ACEIs and ARBs in patients
with significant underlying heart disease (e.g. LV
dysfunction and hypertrophy).269 Recently published
meta-analyses driven by these studies270 demonstrates
substantial benefits from ACEIs and ARBs in the primary
prevention of AF,271 supporting the concept of RAS
Recommendations
 An ACEI or ARB can be used for primary prevention
for AF in patients with heart failure with reduced
ejection fraction.
 ACEI or ARB can be used for primary prevention
for AF in patients with hypertension and LV
hypertrophy.
 ACEI or ARB have no role in secondary prevention for
AF.
 Statin therapy can be used for primary prevention
for AF after coronary artery surgery.
 Therapy with an ACEI, ARB, or statin is not beneficial
for primary prevention of AF in patients without CV
disease.
 Fish oil has no role in primary or secondary preven-
tion of AF.
938 C.-E. Chiang et al.inhibition as an emerging treatment option for the pre-
vention of AF in patients with heart failure and those
with hypertension and LV hypertrophy.270 No definitive
evidence favoring one class of RAS inhibitors over the
other is available. More information on the effects of
ACEIs and ARBs from RCTs is needed for the primary
prevention of AF.
For secondary prevention, three larger prospective
RCTs have yielded negative results, although hypothesis-
generating small clinical studies or retrospective analyses
in selected patient categories have been positive. The
largest secondary prevention study, Gruppo Italiano per lo
Studio della Sopravvivenza nell’Insufficienza cardiac Atrial
Fibrillation (GISSI-AF) enrolling 1442 patients with CV risk
factors (mainly hypertension, 85%) and paroxysmal or
recently cardioverted persistent AF, demonstrated no ef-
fect of valsartan added on top of optimal medical therapy
on the primary endpoint of time to first AF recurrence (HR
0.99; 95% CI 0.85e1.15; p Z 0.84) compared with placebo
at 1-year follow-up.272 The Japanese Rhythm Management
Trial for Atrial Fibrillation (J-RHYTHM) II study in 318 pa-
tients with paroxysmal AF and hypertension showed no
benefit of treatment of hypertension by candesartan
compared with amlodipine, in the reduction in the fre-
quency of paroxysmal AF during 1 year of follow-up.273
The ANgiotensin II anTagonists In Paroxysmal Atrial
Fibrillation (ANTIPAF) study in 425 patients with parox-
ysmal AF without structural heart disease demonstrated
no effect of olmesartan (40 mg/d) compared with placebo
on the primary endpoint of AF burden, detected by tele-
monitoring at 1-year follow-up.274 In light of currently
available data, there is no evidence to make any recom-
mendation for the use of ACEIs and ARBs for secondary
prevention of AF.
12.5.2. Statins
Retrospective, observational, and randomized controlled
studies have reported a lower incidence of postoperative
AF in patients receiving statin therapy. The Atorvastatin for
Reduction of MYocardial Dysrhythmia After cardiac surgery
(ARMYDA-3) trial, the first properly designed RCT, demon-
strate that pretreatment with atorvastatin 40 mg/d starting
7 days prior to elective coronary artery bypass surgery was
associated with a significant reduction in the incidence of
postoperative AF.275 With all studies in the surgical setting
pooled together, the odds ratio for any AF was 0.78 (95% CI,
0.67e0.90; p < 0.001), and for new onset AF, it was 0.66
(95% CI, 0.51e0.84).276 In the Gruppo Italiano per lo Studio
della Sopravvivenza nell’Insufficienza Cardiaca (GISSI-HF)
trial, 2285 patients randomized to rosuvastatin (10 mg/d)
had a nonsignificant reduction of AF by only 13% during a
median follow-up period of 3.7 years.277 The difference
with placebo became statistically significant only after
adjustment for clinical variables and concomitant ther-
apy.277 Clinical data on the primary preventative effects of
statins in AF in other settings were inconsistent, depending
on underlying disease, duration of follow-up, and the his-
tory of AF. While retrospective analysis from epidemiolog-
ical studies and RCTs in patients with LV dysfunction and
heart failure have shown a 20e50% reduction in the inci-
dence of new-onset AF, reports in patients with hyperten-
sion, coronary artery disease, ACSs were less consistent.278There is limited evidence of the efficacy of statins in
secondary prevention of AF in different clinical settings,
and the results are controversial. The only exception is the
postoperative AF. Several prospective randomized
controlled trials have been underway to assess the antiar-
rhythmic value of statins. At present, there is no robust
evidence to make any recommendation for the use of sta-
tins for primary or secondary prevention of AF, except for
AF after coronary artery surgery.
12.5.3. Fish oils
Several mechanisms have been implicated in the antiar-
rhythmic action of U-3 fatty acid. In experimental AF,
induced by ventricular tachypacing,279 and vagal stimula-
tion,280 U-3 fatty acid alleviated shortening of atrial
effective refractory periods, prevented inducibility of AF,
and attenuated structural changes in the atrial myocar-
dium. However, in most of the RCTs in preventing recur-
rence of symptomatic AF, or in the reduction of
postoperative AF, U-3 generally failed.281e283 In a recent
meta-analysis, U-3 fatty acid was unable to decrease AF
recurrence.28412.6. Lifestyle modification
Obesity has been associated with diastolic dysfunction,285
systemic proinflammatory state,286 and atrial enlarge-
ment.287 Fat stores have also been shown to correlate
with incident AF.288 In a single-center, partially blinded,
clinical trial, 150 AF patients were randomized to weight
management (intervention) or general lifestyle advice
(control).289 Both groups underwent intensive manage-
ment of cardiometabolic risk factors. The intervention
group showed a significantly greater reduction, compared
with the control group, in weight (14.3 kg and 3.6 kg,
respectively; p < 0.001) and in AF symptom burden
scores (11.8 and 2.6 points, p < 0.001), symptom severity
scores (8.4 and 1.7 points, p < 0.001), number of epi-
sodes (2.5 and no change, p Z 0.01), and cumulative
duration (692-minute decline and 419-minute increase,
Facts and recommendations
 Long-term sustained weight loss is associated with
significant reduction of AF burden and maintenance
of sinus rhythm.
 RFM, including BMI < 25 kg/m2, BP < 130/80 mmHg,
low-density lipoproteinecholesterol < 100 mg/dL,
triglycerides < 200 mg/dL, and glycated hemoglobin
< 7%, can decrease AF recurrence and symptoms
after AF ablation.
 Cardiopulmonary fitness improvement is effective
for both primary and secondary prevention of AF.
2016 AF Guidelines of THRS/TSOC 939p Z 0.002). Additionally, there was a reduction in
interventricular septal thickness in the intervention and
control groups (1.1 and 0.6 mm, p Z 0.02) and LA area
(3.5 and 1.9 cm2, p Z 0.02). These findings support
therapy directed at weight and risk factors in the man-
agement of AF.289 A long-term study (LEGACY trial) found
a dose effect of weight loss, and weight fluctuation was
related to burden of AF.290 A weight loss  10% resulted
in a six-fold greater probability of arrhythmia-free sur-
vival compared with a weight loss of < 10%. Weight
fluctuation > 5% partially offset this benefit, with a two-
fold increased risk of arrhythmia recurrence. Therefore,
long-term sustained weight loss is associated with sig-
nificant reduction of AF burden and maintenance of sinus
rhythm.290
In the ARREST-AF cohort study, the impact of risk factor
and weight management on AF ablation outcomes was
evaluated.291 Of 281 consecutive patients undergoing AF
ablation, 149 with a body mass index (BMI)  27 kg/m2 and
at least one cardiac risk factor were offered risk factor
management (RFM), including BMI < 25 kg/m2, BP < 130/
80 mmHg, low-density lipoproteinecholesterol < 100 mg/
dL, triglycerides < 200 mg/dL, and glycated hemoglobin <
7%. After AF ablation, all 61 patients who opted for RFM and
88 control individuals were assessed every 3e6 months by
clinic review and 7-day Holter monitoring. RFM resulted in
greater reductions in weight (p Z 0.002) and BP
(p Z 0.006), and better glycemic control (p Z 0.001) and
lipid profiles (p Z 0.01). At follow-up, AF frequency,
duration, symptoms, and symptom severity decreased more
in the RFM group compared with the control group (all
p < 0.001). Drug-unassisted arrhythmia-free survival was
greater in RFM patients compared with control individuals
(p < 0.001). On multivariate analysis, type of AF (p < 0.001)
and RFM (HR 4.8; 95% CI: 2.04e11.4; p < 0.001) were in-
dependent predictors of arrhythmia-free survival. This
study confirmed that aggressive RFM improved the long-
term success of AF ablation, and underscored the impor-
tance of therapy directed at the primary promoters of the
AF substrate to facilitate rhythm control strategies.291
Cardiorespiratory fitness is an independent predictor of
CV outcome and mortality.292 Recent studies have found an
inverse relationship between increased physical activity
and the risk of incident AF.293 In the CARDIO-FIT study, the
role of cardiorespiratory fitness and the incremental
benefit of cardiorespiratory fitness improvement on rhythm
control was evaluated in obese individuals with AF.294
Arrhythmia-free survival with and without rhythm control
strategies was greatest in patients with high cardiorespi-
ratory fitness compared to adequate or low cardiorespira-
tory fitness (p < 0.001 for both). AF burden and symptom
severity decreased significantly in the group with cardio-
respiratory fitness gain  2 metabolic equivalents (METs) as
compared to < 2 METs group (p < 0.001 for all).
Arrhythmia-free survival with and without rhythm control
strategies was greatest in those with METs gain  2
compared to those with METs gain < 2 in cardiorespiratory
fitness (p < 0.001 for both). It is concluded that cardiore-
spiratory fitness predicts arrhythmia recurrence in obese
individuals with symptomatic AF. Improvement in cardio-
respiratory fitness augments the beneficial effects of
weight loss.294 The association of cardiorespiratory fitnessand incident AF in a primary prevention setting was tested
in a large, multiracial cohort that underwent graded ex-
ercise treadmill testing.295 A total of 64,561 adults without
AF underwent exercise treadmill testing at a tertiary care
center. During a median follow-up of 5.4 years (inter-
quartile range, 3e9 years), 4616 new cases of AF were
diagnosed. After adjustment for potential confounders,
one higher metabolic equivalent achieved during treadmill
testing was associated with a 7% lower risk of incident AF
(HR, 0.93; 95% CI, 0.92e0.94; p < 0.001). The magnitude of
the inverse association between cardiorespiratory and
incident AF was greater among obese compared with non-
obese individuals (p for interaction Z 0.02). Therefore,
there is a graded, inverse relationship between cardiore-
spiratory fitness and incident AF, especially among obese
patients.29513. Ablation therapy
During the past decade, catheter ablation of AF has
developed rapidly from an experimental unproven proced-
ure to a commonly performed ablation procedure in the
majority of electrophysiological laboratories throughout
the world. The main objective of this section is to provide
foundation of knowledge and literature review for those
involved with catheter ablation of AF.
13.1. Rationale for eliminating AF with catheter
ablation
Most current available RCTs regarding rhythm control versus
rate control of AF were based on the strategy. These clinical
trials clearly show that the strategy of rhythm control does
not achieve the potential benefits.296 However, there are
some studies suggesting that the clinical benefit of main-
tenance of sinus rhythm (SR) may be preferred if achieved
other than through drug therapy. There are several reasons
to perform the ablation procedure for treatment of AF. In
recent years, several randomized trials have demonstrated
that catheter ablation (including paroxysmal and persis-
tent) was superior to antiarrhythmic therapy in the pre-
vention of recurrent and symptomatic AF.297e303 The
primary justification for an AF ablation is the presence of
symptomatic AF with a goal to improve the quality of life of
patients.58,301 Thus, the primary selection criterion for
940 C.-E. Chiang et al.catheter ablation should be the presence of symptomatic
AF. The benefit of AF ablation has not been demonstrated in
asymptomatic patients. Second, the transport function of
the LA improved after ablation.304 Last, there is an associ-
ation between AF and increase risk of cerebral thrombo-
embolism, developing heart failure and increased
mortality. The risk of stroke was low after catheter abla-
tion.305,306 However, large prospective multicenter RCTs
are needed to compare with rate control strategy.307
13.2. Outcomes of catheter ablation and
complications
Catheter ablation is usually performed in patients with
symptomatic paroxysmal or persistent AF that is resistant
to at least one AAD, irrespective of the presence of struc-
tural heart disease. This is supported by the results of
multiple randomized trials by comparing AAD treatment
with catheter ablation (Table 19).297e303 Data on direct
comparison of catheter ablation as first ablation therapy
were available in one randomized trial.297 Considering the
potential AF catheter ablation in paroxysmal AF in patients
with minimal or no heart disease, and the relative safety of
the technique in the experienced centers, ablation could
be considered as an initial therapy in selected patients. For
patients with long-standing persistent AF, the treatment
strategies and the benefiterisk ratio of catheter ablation
are less well established, because extensive ablation and
multiple procedures are usually required.308 Consideration
of different types of antiarrhythmic medication should be
individualized prior to ablation.
A world survey on the efficacy and safety of catheter
ablation of AF has been published.196 The efficacy rate of
free from AADs in patients previously refractory to drugs
was 70%, and an additional 10% efficacy rate in the pres-
ence of the previously ineffective drug. More than one
procedure was required in 27% of patients. According to the
survey, catheter ablation is associated with significant
complications. The incidence of major complications was
4.5% and the overall mortality was 0.7%. Rarer complica-
tions may result in permanent injury, requiring intervention
and prolonged hospitalization.Table 19 Randomized controlled study comparing catheter abl
Study PAF/Per AF Patients
(ablation/AAD)
Ablatio
Wazni 2005297 96% PAF (primary
therapy)
33/37 PVI
Oral 2006298 100% Per AF 77 (32 re-do)/69
(77% cross-over)
PVIþLA
Pappone 2006299 100% PAF 99/99 PVI þ
Stabile 2006300 67% PAF 68/69 PVI þ
Jais 2008301 100% PAF 53/59 PVI þ
Wilber 2010302 100% PAF 106/61 PVI 
Mont 2014303 100% Per AF 98/48 PVI 
AADZ antiarrhythmic drug; CFE Z complex fractionated atrial elect
AF Z persistent atrial fibrillation; PVI Z pulmonary vein isolation.13.3. Pre-ablation assessment
Prior to an ablation procedure, all patients should undergo:
(1) 12-lead ECG and/or Holter recording to document AF;
(2) a transthoracic ECG to identify/exclude underlying
structural heart disease; (3) additional imaging, e.g. CT or
MRI, demonstrates individual three-dimensional geometry
and provides quantification of atrial fibrosis; (4) exclusion
of LA thrombosis by TEE prior to the procedure (usually
within 48 hours) or during the procedure. Appropriate
anticoagulation should be considered to bridge the time of
TEE and the procedure itself. LA venography was recom-
mended to exclude the heavy smoke or thrombus immedi-
ately prior to the procedure; and (5) barium esophagogram
prior to ablation to demonstrate the location of esophagus,
and avoid injury.
13.4. Catheter ablation strategy
Identification of initiating triggers allows prevention of AF
recurrence by ablation at the sites of the triggers. It is
well known that PV is the major site of ectopic foci
initiating paroxysmal AF.22,309 PV ablation is considered
the primary choice for first-time ablation in paroxysmal
AF, and even in persistent, and long-lasting AF patients.310
The end-points for different PV isolation approach is
either elimination of amplitude reduction of the ablation
sites, elimination of PV potentials recorded from circular
catheter (or dissociation), and/or exit block from the
PVs.311 A randomized trial showed that isolation of larger
circumferential lesion is more effective than segmental
ablation,312 owing to the elimination of non-PV ectopies
near the PV ostium.313 Non-PV triggers initiating AF can be
identified in up to one-third of AF patients. Elimination of
the non-PV ectopies resulted in elimination of AF.314 The
sites of non-PV triggers include superior vena cava, crista
terminalis, coronary sinus, posterior wall of LA, and liga-
ment of Marshall. Furthermore, non-PV reentrant sources
of AF could be identified in the RA and LA, which were
identified by frequency analysis and/or high density
mapping technique.315,316 Some patients with paroxysmal
AF with extensive atrial modeling (or positive inducibility)ation and antiarrhythmic therapy as rhythm control therapy.
n AF freedom
ablation
AF freedom
AAD
Follow-up
duration
85% 21% 9 mo
lines 74% (Multi) 58% 12 mo
Mitral line þ CTI 85% 35% 12 mo
mitral lines 65% 8.7% 12 mo
non-PV 89% (Multi) 23% 12 mo
line, CFEs 66% (combined
end-points)
16% 9 mo
line, CFEs 70.4% 43.79% 12 mo
rograms, CTIZ cavotricuspid isthmus; PAFZ paroxysmal AF; Per
2016 AF Guidelines of THRS/TSOC 941and nearly all patients with nonparoxysmal AF may
require substrate modification to improve the outcome in
addition to elimination the triggers.317 Substrate modifi-
cation included: (1) linear ablation of the LA and/or RA;
(2) complex fractionated atrial electrograms318e320; and
(3) elimination of small-radius reentry as rotors.320 How-
ever, recent study showed that no reduction in the rate of
recurrent AF when either linear ablation or ablation of
complex fractionated electrograms was performed in
addition to PV isolation.321 The wide variation in the use
of additional techniques and in the choice of endpoints
reflects the uncertainties and lack of guidance in addi-
tional to PV ablation in persistent AF.
In the right atrium, cavotricuspid isthmus linear ablation
is required for isthmus dependent AFL, paroxysmal AF with
inducible isthmus dependent AFL and in all patients with
nonparoxysmal AF. The efficacy of cavotricuspid isthmus
ablation was high, with acute success rate of 97%. Ablation
could be considered as the first line therapy compared to
antiarrhythmic medication in patients with sustained
symptomatic typical AFL with high efficacy and a positive
impact of quality of life, low complication and lower
comorbidity.322,323
13.5. Follow-up considerations
Regarding the anticoagulation use following catheter
ablation, anticoagulant is recommended to be prescribed
for a minimum of 2 months after the catheter ablation in
high-risk patients. Individual stroke risk of patients shall be
considered to determine whether oral anticoagulation
should be continued. Although recent cohort studies
demonstrated that the patients without symptomatic AF
had a lower risk of vascular events or death, discontinua-
tion of warfarin therapy postablation is generally not rec-
ommended in patients with high risk of stroke
(CHA2DS2VASc  2), as multiple comorbidity exist in these
patients.306 The usefulness of the CHA2DS2VASc score in the
prediction of adverse events after catheter ablations has
been proved and validated.324
Symptom-based follow-up may be sufficient, as symp-
tom relief is the main aim of AF ablation. To obtain infor-
mation to compare success rates following different
procedures and to improve ablation techniques, system-
atic, standardized ECG monitoring is needed. Expert
consensus recommends an initial follow-up visit at
3 months, with 6-monthly intervals thereafter for at least
2 years. The true AF recurrence rate will be markedly
underestimated by a longer recording duration.Table 20 Summary of surgical ablation efficacy and outcome.
Study Per AF Number Long AF
Izumoto 2000325 100% 104 0%
McCarthy 2000326 78% 100 23%
Schaff 2000327 80% 221 25%
Je 2009328 87% 550 d
Weimar 2012329 52% 212 100%
Per AF Z persistent atrial fibrillation; periop Z perioperative; PPM Z13.6. Atrioventricular node ablation and
modification
Atrioventricular node (AVN) ablation provides highly
effective control of ventricular rate in patients with AF.
Complete heart block is achieved by selective catheter-
mediated destruction of the AVN or His bundle, with radi-
ofrequency current serving as the predominant source of
ablation energy. Ablation of the AVN is a palliative rate
control therapy but irreversible procedure and is therefore
reasonable in patients in whom pharmacological rate con-
trol or rhythm control with drugs and/or ablation has
failed. In such patients, AVN ablation improves quality of
life and renders mortality similar to death rates in the
general population. It is reasonable to assume that patients
with reduced LV function may require biventricular pacing
after AVN ablation to prevent deterioration of LV function.
In patients without LV dysfunction, it is not established at
present whether biventricular pacing is needed: some data
suggest that biventricular pacing may be beneficial, and LV
failure should be considered in patients with right ven-
tricular pacing.
13.7. Surgical AF ablation
The Maze procedure was the first surgical technique
developed to ablate AF and was developed before PV
ablation strategy. Currently the conventional Cox III Maze
procedure with cut-and-saw remains the cold standard of
surgical ablation, even though many energy source
including cryoablation, bipolar ablation, and microwave are
evolving in clinical service. Based on the reports from major
centers, the efficacy of AF prevention is high, with poten-
tial sinus node injury/permanent pacemaker implantation,
recurrence of organized AF/AFL and reconnection of PV
(Table 20).325e329
Many studies have demonstrated that treating AF results
in an improved quality of life, fewer long-term strokes and
improved long-term survival while adding no risk to the
overall surgical procedure. Moreover, the major cardiology
and surgery societies recommend that concomitant AF
surgery be performed in all cases when feasible. Patients
undergoing coronary artery bypass graft and mitral/aortic
valve surgery who have symptomatic paroxysmal AF may
consider concomitant surgical PV ablation, while those with
long-standing persistent AF, right atrial linear ablation
should include a Maze procedure.
Ablation strategies have been deployed with the inten-
tion of curing AF in several patient populations. Long-termMortality PPM Efficacy
4.9% (1 y) 6% 65% (3 y)
1% (periop), 5% (late) 6% 90% (3 y)
1.4% (early) 3.2% 70% (3 y)
1.6% (early), 4.2% (3 y) 2.3% 82.2% (5 y)
1.3% (30 d), 2.6% (late) 8% 90% (2 y)
permanent pacemaker.
942 C.-E. Chiang et al.follow-up of these patients suggests that sinus rhythm is
better preserved than with AADs. The majority of studies
have recruited patients with symptomatic paroxysmal AF
and no or minimal structural heart disease. In general,
catheter ablation should be reserved for patients with AF
that remains symptomatic despite optimal medical ther-
apy, including rate and rhythm control (Figure 2).Recommendations
 Catheter ablation is usually performed in patients
with symptomatic paroxysmal or persistent AF that
is resistant to at least one antiarrhythmic drug,
irrespective of the presence of structural heart
disease.
 Stand-alone PV ablation is the primary choice of
ablation strategy for first-time ablation, even in
patients with persistent AF.
 The usefulness of the CHA2DS2-VASc score in the
prediction of adverse events after catheter ablations
has been proven and validated.
 Ablation of the AVN is a palliative rate control
therapy.
 Concomitant surgical PV ablation should be consid-
ered in all AF patients undergoing coronary artery
bypass graft and mitral/aortic valve surgery.Acknowledgments
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